<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">72908</article-id><article-id pub-id-type="doi">10.7554/eLife.72908</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Structural basis of <italic>Plasmodium vivax</italic> inhibition by antibodies binding to the circumsporozoite protein repeats</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-190514"><name><surname>Kucharska</surname><given-names>Iga</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6150-3419</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251453"><name><surname>Hossain</surname><given-names>Lamia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251454"><name><surname>Ivanochko</surname><given-names>Danton</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251455"><name><surname>Yang</surname><given-names>Qiren</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179735"><name><surname>Rubinstein</surname><given-names>John L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0566-2209</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40981"><name><surname>Pomès</surname><given-names>Régis</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3068-9833</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-126745"><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7602-3995</contrib-id><email>jean-philippe.julien@sickkids.ca</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Program in Molecular Medicine, The Hospital for Sick Children Research Institute</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff2"><label>2</label><institution>Department of Biochemistry, University of Toronto</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff3"><label>3</label><institution>Department of Medical Biophysics, University of Toronto</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff4"><label>4</label><institution>Department of Immunology, University of Toronto</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Frank</surname><given-names>Aaron</given-names></name><role>Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Faraldo-Gómez</surname><given-names>José D</given-names></name><role>Senior Editor</role><aff><institution>National Heart, Lung and Blood Institute, National Institutes of Health</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>13</day><month>01</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e72908</elocation-id><history><date date-type="received" iso-8601-date="2021-08-09"><day>09</day><month>08</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-01-12"><day>12</day><month>01</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-09-01"><day>01</day><month>09</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.08.31.458469"/></event></pub-history><permissions><copyright-statement>© 2022, Kucharska et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Kucharska et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-72908-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-72908-figures-v2.pdf"/><abstract><p>Malaria is a global health burden, with <italic>Plasmodium falciparum</italic> (Pf) and <italic>Plasmodium vivax</italic> (Pv) responsible for the majority of infections worldwide. Circumsporozoite protein (CSP) is the most abundant protein on the surface of <italic>Plasmodium</italic> sporozoites, and antibodies targeting the central repeat region of CSP can prevent parasite infection. Although much has been uncovered about the molecular basis of antibody recognition of the PfCSP repeats, data remains scarce for PvCSP. Here, we performed molecular dynamics simulations for peptides comprising the PvCSP repeats from strains VK210 and VK247 to reveal how the PvCSP central repeats are highly disordered, with minor propensities to adopt turn conformations. Next, we solved eight crystal structures to unveil the interactions of two inhibitory monoclonal antibodies (mAbs), 2F2 and 2E10.E9, with PvCSP repeats. Both antibodies can accommodate subtle sequence variances in the repeat motifs and recognize largely coiled peptide conformations that also contain isolated turns. Our structural studies uncover various degrees of Fab-Fab homotypic interactions upon recognition of the PvCSP central repeats by these two inhibitory mAbs, similar to potent mAbs against PfCSP. These findings augment our understanding of host<italic>-Plasmodium</italic> interactions and contribute molecular details of Pv inhibition by mAbs to unlock structure-based engineering of PvCSP-based vaccines.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>P. vivax</italic></kwd><kwd>circumsporozoite protein</kwd><kwd>antibodies</kwd><kwd>structural biology</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001804</institution-id><institution>Canada Research Chairs</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rubinstein</surname><given-names>John L</given-names></name><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pomès</surname><given-names>Régis</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000165</institution-id><institution>Sick Kids Foundation</institution></institution-wrap></funding-source><award-id>Restracomp Fellowship</award-id><principal-award-recipient><name><surname>Kucharska</surname><given-names>Iga</given-names></name><name><surname>Ivanochko</surname><given-names>Danton</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007631</institution-id><institution>Canadian Institute for Advanced Research</institution></institution-wrap></funding-source><award-id>Azrieli Global Scholar program</award-id><principal-award-recipient><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012171</institution-id><institution>Ontario Research Foundation</institution></institution-wrap></funding-source><award-id>Early Researcher Award program</award-id><principal-award-recipient><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Biophysical and structural studies reveal how two inhibitory antibodies targeting CSP on malaria-causing <italic>Plasmodium vivax</italic> parasites lock its intrinsically flexible repeat into predominant coiled conformations, contributing molecular details of Pv inhibition by antibodies to enable structure-based engineering of PvCSP-based vaccines.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Malaria is a major public health concern, with an estimated 409,000 deaths in 2019 (<xref ref-type="bibr" rid="bib87">World Health Organization, 2020</xref>). Human malaria is caused by <italic>Plasmodium</italic> parasites, with the majority of cases attributed to <italic>Plasmodium falciparum</italic> (Pf) and <italic>Plasmodium vivax</italic> (Pv) (<xref ref-type="bibr" rid="bib44">Lover et al., 2018</xref>). Pv is the predominant <italic>Plasmodium</italic> spp. in circulation for a majority of countries outside of Africa (~75% of cases in South and North America, ~50% of cases in the Southeast Asia region, and ~30% in the Eastern Mediterranean region; <xref ref-type="bibr" rid="bib87">World Health Organization, 2020</xref>). Despite overall lower mortality compared to Pf malaria, Pv infection can cause debilitating disease, including fever, myalgia, chronic anemia, reduced birthweight, and increased risk of neonatal death (<xref ref-type="bibr" rid="bib4">Alexandre et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Bardají et al., 2017</xref>; <xref ref-type="bibr" rid="bib24">Genton et al., 2008</xref>).</p><p>Circumsporozoite protein (CSP) is the most abundant protein on the surface of all <italic>Plasmodium</italic> sporozoites and is necessary for parasite development and infection (<xref ref-type="bibr" rid="bib15">Cerami et al., 1992</xref>; <xref ref-type="bibr" rid="bib49">Ménard et al., 1997</xref>; <xref ref-type="bibr" rid="bib58">Nguitragool et al., 2017</xref>). CSP contains an unusual central region consisting of multiple, short amino acid repeats whose sequence depends on the <italic>Plasmodium</italic> species (<xref ref-type="bibr" rid="bib16">Chenet et al., 2012</xref>; <xref ref-type="bibr" rid="bib72">Rich et al., 2000</xref>; <xref ref-type="bibr" rid="bib80">Tahar et al., 1998</xref>). The PvCSP central region is composed of nonapeptides GDRA(A/D)GQPA and ANGAGNQPG characteristic of strains VK210 and VK247, respectively (<xref ref-type="bibr" rid="bib5">Arnot et al., 1985</xref>; <xref ref-type="bibr" rid="bib73">Rosenberg et al., 1989</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Unlike the 4-amino acid (aa)-long motifs of Pf and <italic>Plasmodium berghei</italic> (Pb) CSP, which are rich in asparagine and proline residues, PvCSP repeats are longer and consist primarily of glycine and alanine residues (~50% of all residues). Moreover, ~26% of the PvCSPvk210 central repeat region consists of charged residues, including arginine and aspartic acid residues. Both VK210 and VK247 strains have worldwide distribution (<xref ref-type="bibr" rid="bib17">Cheng et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Kain et al., 1992</xref>; <xref ref-type="bibr" rid="bib79">Soares et al., 2020</xref>), and VK210 appears to be a major target of the humoral immune response in studied populations (<xref ref-type="bibr" rid="bib27">González et al., 2001</xref>; <xref ref-type="bibr" rid="bib38">Kim et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Soares et al., 2020</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Comparison of PvCSPvk210 and PvCSPvk247 repeat sequences.</title><p>(<bold>A</bold>) Schematic representations of PvCSPvk210 and PvCSPvk247 sequences, each including an N-terminal domain, central repeat region, and C-terminal domain. Colored blocks represent repeat motifs. The sequence of peptides used in circular dichroism (CD) spectroscopy studies is shown below. (<bold>B</bold>) Superimposition of the CD spectra obtained for PvCSPvk210 (top panel) and PvCSP247 peptides (bottom panel). PvCSPvk210 peptides 210-1, 210-2, 210-3, 210-4, and 210-5 are colored from navy to light blue; PvCSPvk247 peptides are depicted in green (247-1), yellow (247-2), and orange (247-3), respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig1-v2.tif"/></fig><p>The central region of CSP is immunodominant, and antibodies targeting the repeats can inhibit sporozoite infection (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Mishra et al., 2012</xref>; <xref ref-type="bibr" rid="bib55">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Oyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Oyen et al., 2020</xref>; <xref ref-type="bibr" rid="bib65">Pholcharee et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>; <xref ref-type="bibr" rid="bib68">Potocnjak et al., 1980</xref>; <xref ref-type="bibr" rid="bib81">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib84">Triller et al., 2017</xref>; <xref ref-type="bibr" rid="bib85">Wang et al., 2020</xref>). The PfCSP central repeat is a major component of the most advanced malaria vaccine to date, RTS,S/AS01 (<xref ref-type="bibr" rid="bib3">Adepoju, 2019</xref>; <xref ref-type="bibr" rid="bib20">Draper et al., 2018</xref>), and PvCSP or PvCSP-derived peptides are present in various clinical vaccine candidates against Pv (<xref ref-type="bibr" rid="bib53">Mueller et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Mueller et al., 2015</xref>). Effective pre-erythrocytic stage vaccines are highly desirable to reduce the number of primary infections, and in the case of Pv, to consequently prevent the establishment of hypnozoites that can lead to multiple relapses (<xref ref-type="bibr" rid="bib41">Krotoski et al., 1982</xref>).</p><p>Although not much is known about the molecular basis of PvCSP recognition by inhibitory antibodies, a positive statistical association between the level of antibodies against the repeat region of PvCSP and protection has previously been established (<xref ref-type="bibr" rid="bib88">Yadava et al., 2014</xref>). Anti-PvCSP species-specific monoclonal antibodies (mAbs) 2F2 and 2E10.E9 were generated in mice after immunization with radiation-attenuated Pv sporozoites of strains VK210 and VK247, respectively (<xref ref-type="bibr" rid="bib57">Nardin et al., 1982</xref>). Incubation of Pv sporozoites with mAbs 2F2 and 2E10.E9 results in significantly reduced sporozoite infectivity, and thus despite a limited molecular understanding of their recognition, both antibodies have been valuable research tools in studies of Pv sporozoites (<xref ref-type="bibr" rid="bib14">Cabrera-Mora et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Gimenez et al., 2017</xref>; <xref ref-type="bibr" rid="bib51">Miyazaki et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Roth et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Teixeira et al., 2014</xref>). Interestingly, a recent study reported that sporozoites attenuated with low concentrations of mAb 2F2 were significantly reduced in size and had lower DNA content, indicating post-hepatocyte-invasion antibody inhibition of liver stage development (<xref ref-type="bibr" rid="bib74">Roth et al., 2018</xref>).</p><p>Here, we present a detailed molecular analysis of the PvCSP repeat region and its recognition by inhibitory mAbs 2F2 and 2E10.E9. Molecular dynamics (MD) simulations on PvCSP-derived repeat peptides indicate that in the absence of interacting mAbs, the PvCSP repeat is largely disordered. Our structural studies reveal how mAbs 2F2 and 2E10.E9 lock PvCSP repeat peptides in a predominant coiled conformation, with antibody germline-encoded aromatic residues contributing significantly to the antigen contacts. Moreover, we describe how mAb 2E10.E9 engages in head-to-head homotypic interactions when targeting PvCSP in a similar manner as previously described human mAbs against PfCSP (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Oyen et al., 2018</xref>; <xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>) and a murine mAb against PbCSP (<xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>PvCSP repeat peptides are structurally disordered and behave like harmonic springs</title><p>Due to the variety of PvCSP repeat sequence motifs, we created an extensive list of peptides for circular dichroism (CD) spectroscopy and MD simulations studies (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig1">Figure 1A</xref>) to examine the structural propensities of 18- and 27-aa-long motifs from the PvCSPvk210 and PvCSPvk247 repeats. CD spectra of all analyzed peptides were indicative of a lack of secondary structure, with minima at ~200 nm (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><p>For a finer dissection of potential minor secondary structure propensities, we performed all-atom MD simulations on 27-aa peptides derived from PvCSPvk210 and PvCSPvk247 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). All analyzed peptides were highly disordered in solution and adopted a large ensemble of conformations (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), similar to peptides derived from PfCSP and PbCSP (<xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>). Secondary structure was present mainly in the form of transient hydrogen-bonded β-turns (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The propensity of individual residues to form turns varied from 0 to ~60%, with PvCSPvk210 peptides displaying slightly lower averaged turn propensity (~15–20%) than PvCSPvk247 peptides (~23–26%) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). PvCSPvk210 peptides containing (GDRAAGQPA)<sub>2</sub> motifs (210-7 and -9), as well as the last repeat of the 247-3 peptide (GNGAGGQAA), were the only motifs with a significant propensity to form helices (&gt;20%).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Conformational flexibility of PvCSPvk210 and PvCSPvk247 peptides.</title><p>(<bold>A</bold>) Superposition of the conformations of peptides resulting from molecular dynamics (MD) simulations at every 2 ns and aligned to the conformational median structure. (<bold>B</bold>) Example snapshots of the highest (peptides 210-7, 210-8, 210-9, and 247-3) or the second highest (peptides 210-6, 247-1, 247-2) propensity β-turn for each peptide. Color coding of atoms: oxygen (red), nitrogen (blue), and hydrogen (white). For clarity, only the hydrogen atom involved in the H-bonded turn is shown. H-bond between C=O of residue <italic>i</italic> and N–H of residue <italic>i + 3</italic> is shown as a gray line. (<bold>C</bold>) Secondary structure propensity at each residue, averaged over 20 replicas and computed using the Dictionary of Secondary Structure for Proteins (DSSP) criteria (<xref ref-type="bibr" rid="bib56">Nagy and Oostenbrink, 2014</xref>). (<bold>D</bold>) Elastic modulus of peptides computed from MD simulations. The reversible work or free energy (ΔG) for extension and compression of the peptide is plotted as a function of equilibrium end-to-end distances (<italic>d<sub>EE</sub></italic>) (solid line). The data is fitted to the quadratic function of elastic potential energy (black dashed line). For each peptide, the estimated values of <italic>k</italic> (elastic modulus), <italic>d</italic><sub>0</sub> (equilibrium <italic>d<sub>EE</sub></italic>), and R<sup>2</sup> (regression coefficient to indicate quality of fit) are shown. Shading represents standard error of mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Time evolution of structural properties of PvCSP peptides.</title><p>Properties are averaged over 20 replicas, with the shading area representing standard error of the mean. (<bold>A</bold>) H-bond turn propensity (<italic>X<sub>turn</sub></italic>). (<bold>B</bold>) Number of peptide-peptide H-bonds per residue (<italic>X<sub>HB</sub></italic>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Ensemble-averaged backbone-backbone H-bonding maps for each PvCSP peptide sequence.</title><p>A forward H-bond forms between C=O (acceptor) of residue <italic>i</italic> and N–H (donor) of residue <italic>i + n</italic> (upper diagonal), while the reverse forms a reverse H-bond (lower diagonal). Within the diagonal represents local interactions, which forms by a pair of residues that are less than seven residues apart. The color of each square represents the H-bond propensities formed by the interacting residues. The gray and the pink arrows indicate the highest and the second highest propensity turn, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig2-figsupp2-v2.tif"/></fig></fig-group><p>In order to estimate the elastic modulus of these peptides with intrinsically low secondary structure propensities, peptides were modeled as Hookean springs (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), in which the force needed to extend or compress a spring by some distance is proportional to that distance, and the underlying energy function is quadratic (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>). The PMF or free energy governing changes in the peptide’s end-to-end distance was computed and fit to a quadratic function. The excellent data fits (R<sup>2</sup> = 0.91–0.97) suggest that in aqueous solution, peptides derived from the PvCSP repeats behave like harmonic springs. On average, the elastic modulus was ~3–5 cal/(mol Å<sup>2</sup>), with the highest values (stiffest peptide) observed for peptide 247-2 (4.9 ± 0.2 cal/(mol Å<sup>2</sup>)) and lowest (most flexible peptide) observed for peptide 247-1 (3.2 ± 0.2 cal/(mol Å<sup>2</sup>)).</p></sec><sec id="s2-2"><title>Molecular basis of 2F2 recognition of the PvCSPvk210 central repeat</title><p>To gain insights into how inhibitory mAb 2F2 binds to a largely disordered, elastic repeating PvCSPvk210 epitope, we performed isothermal titration calorimetry (ITC) with PvCSPvk210 repeat peptides representative of the different sequence motifs contained within the central repeat region (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). 2F2 Fab binds to all tested peptides containing two repeats with similar affinity, with a slight preference for peptide 210-3 (GDRADGQPAGDRAAGQPA; 13.8 nM) over 210-2 (GDRAAGQPAGDRAAGQPA; 37.5 nM) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), with other peptides displaying intermediate affinities (17.1–19.1 nM). Peptides 210-3 and 210-2 differ in the fifth residue of the first repeat, which is an aspartic acid for peptide 210-3 and an alanine for peptide 210-2 (GDRA(<underline>D/A</underline>)GQPA).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>2F2 Fab binding to PvCSPvk210 repeat peptides.</title><p>(<bold>A</bold>) Affinities of 2F2 Fab for peptides 210-1, 210-2, 210-3, 210-4, and 210-5 as measured by isothermal titration calorimetry (ITC). Open circles represent independent measurements. Mean binding constant (K<sub>D</sub>) and binding stoichiometry (N) values are shown above the corresponding bar. Error bars represent SEM. (<bold>B</bold>) Upper panel: sequences of peptides used in ITC experiments with variable residues underlined. Dark gray denotes the core epitope of the peptide resolved in all the X-ray crystal structures, and light gray shading indicates residues resolved in the corresponding X-ray crystal structures. Bottom panel: comparison of the conformations of PvCSP210 peptides in X-ray crystal structures. PvCSPvk210 peptides are colored from navy to light blue, with the residues adopting one turn of a 3<sub>10</sub>-helix depicted in pink. (<bold>C</bold>) Top and side views of the 210-4 peptide (light blue) in the binding groove of the 2F2 Fab shown as surface representation (heavy chain [HC] shown in green and kappa chain [KC] shown in white). (<bold>D</bold>) Comparison of the conformations adopted by the core epitope of peptides 210-1, 210-2, 210-3, 210-4, and 210-5 when bound to 2F2. (<bold>E</bold>) Detailed interactions between Fab 2F2 and peptide 210-4. H-bonds and salt bridges are shown as black dashes, peptide 210-4 is shown in light blue, HC is shown in green, and KC is shown in gray. Fab residues are annotated with H or K letters to indicate heavy and kappa light chain, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Isothermal titration calorimetry (ITC) measurements of 2F2 Fab binding to peptides 210-1 (<bold>A</bold>), 210-2 (<bold>B</bold>), 210-3 (<bold>C</bold>), 210-4 (<bold>D</bold>), and 210-5 (<bold>E</bold>).</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Stereo-image of the composite omit map electron density contoured at 1.0–1.2 sigma for peptides 210-1 (<bold>A</bold>), 210-2 (<bold>B</bold>), 210-3 (<bold>C</bold>), 210-4 (<bold>D</bold>), and 210-5 (<bold>E</bold>).</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Interactions between germline-encoded aromatic residues in anti-CSP monoclonal antibodies (mAbs) and repeat peptides.</title><p>Heavy chain complementarity-determining region (HCDR) and kappa chain complementarity-determining region (KCDR) are colored green and gray, respectively. The positions of germline-encoded tryptophan and tyrosine residues interacting with the peptides are highlighted with black dashed circles. (<bold>A</bold>) 1210 Fab (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>) and NANP<sub>5</sub> peptide (pink); (<bold>B, D</bold>) 2E10.E9 Fab and 247-4 peptide (orange); (<bold>C, E</bold>) 2F2 Fab and 210-3 peptide (blue). (<bold>F</bold>) Interactions between peptide proline residues and H.Trp52 in 1210 Fab (left panel) and H.Trp50 in 2E10.E9 Fab (right panel). (<bold>G</bold>) Residues <sub>8</sub>PAG<sub>10</sub> of PvCSPvk210 peptides adopt one turn of a 3<sub>10</sub>-helix, which is positioned in the pocket formed by aromatic residues of KCDR1 and 3.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Electrostatic surface potential of monoclonal antibodies (mAbs) 2F2 (<bold>A</bold>), 2E10.E9 (<bold>B</bold>), 1210 (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>) (<bold>C</bold>), and 3D11 (<xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>) (<bold>D</bold>) bound to CSP peptides.</title><p>Scale: –5 kT e<sup>–1</sup> (red) to +5 kT e<sup>–1</sup> (blue).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig3-figsupp4-v2.tif"/></fig></fig-group><p>Next, we co-crystalized the 2F2 Fab with five different peptides derived from PvCSPvk210 (210-1, 210-2, 210-3, 210-4, and 210-5, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>) to gain molecular insights into the binding mode and cross-reactivity of mAb 2F2 binding to PvCSPvk210. The crystal structures were solved to resolutions ranging from 1.97 Å to 2.67 Å (<xref ref-type="table" rid="table1">Table 1</xref>). 2F2 recognizes the core epitope (<sub>2</sub>DRA(D/A)GQ<underline>PAG</underline>D<sub>11</sub>) of all PvCSPvk210 peptides in an almost identical coil conformation peptide backbone root-mean-square deviation (RMSD 0.10–0.28 Å) with two consecutive β-turns observed for residues <sub>7</sub>QPAGD<sub>11</sub> (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) forming one turn of a 3<sub>10</sub>-helix, thus consistent with the moderate secondary structure propensities observed for the unliganded PvCSPvk210 repeats (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The co-crystal structures also provide molecular insights into the cross-reactivity of 2F2 to different types of PvCSPvk210 repeat motifs (<sub>1</sub>GDRA(<underline>D/A</underline>)GQPA<sub>9</sub>). The sidechains of D/A<sub>5</sub> point up and away from the 2F2 paratope and do not significantly contribute to the 2F2 Fab-peptide interaction, helping to explain the similar binding affinities to the different peptides containing this variation (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). 2F2 also binds the 210-5 peptide containing a unique repeat C-terminal of the central region (<sub>1</sub>GDRAAGQPAG<underline>N</underline>GA<underline>GG</underline>Q<underline>A</underline>A<sub>18</sub>); however, the electron density of residues 12–18 C-terminal of the bound core peptide motif is weak in the co-crystal structure, thus providing limited structural insight into this peptide region and suggesting it does not make strong interactions with 2F2 (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>X-ray crystallography data collection and refinement statistics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">2F2-210-1</th><th align="left" valign="bottom">2F2-210-2</th><th align="left" valign="bottom">2F2-210-3</th><th align="left" valign="bottom">2F2-210-4</th><th align="left" valign="bottom">2F2-210-5</th><th align="left" valign="bottom">2E10-247-2</th><th align="left" valign="bottom">2E10-247-3</th><th align="left" valign="bottom">2E10-247-4</th></tr></thead><tbody><tr><td align="left" valign="bottom">Beamline</td><td align="left" valign="bottom">APS 23-ID-B</td><td align="left" valign="bottom">APS 23-ID-D</td><td align="left" valign="bottom">APS 23-ID-B</td><td align="left" valign="bottom">APS 23-ID-B</td><td align="left" valign="bottom">APS 23-ID-D</td><td align="left" valign="bottom">APS 23-ID-B</td><td align="left" valign="bottom">APS 23-ID-B</td><td align="left" valign="bottom">APS 23-ID-D</td></tr><tr><td align="left" valign="bottom">Wavelength (Å)</td><td align="left" valign="bottom">1.033167</td><td align="left" valign="bottom">1.033167</td><td align="left" valign="bottom">1.033167</td><td align="left" valign="bottom">1.033167</td><td align="left" valign="bottom">1.033167</td><td align="left" valign="bottom">1.033167</td><td align="left" valign="bottom">1.033167</td><td align="left" valign="bottom">1.033200</td></tr><tr><td align="left" valign="bottom">Space group</td><td align="left" valign="bottom">P 1</td><td align="left" valign="bottom">C 2</td><td align="left" valign="bottom">C 2</td><td align="left" valign="bottom">P 1</td><td align="left" valign="bottom">C 2</td><td align="left" valign="bottom">P 3<sub>1</sub></td><td align="left" valign="bottom">P 2<sub>1</sub></td><td align="left" valign="bottom">P 1</td></tr><tr><td align="left" valign="bottom">Cell dimensions</td><td align="left" valign="bottom">71.5, 81.4, 82.3</td><td align="left" valign="bottom">92.9, 60.4, 158.3</td><td align="left" valign="bottom">92.6, 60.8, 81.4</td><td align="left" valign="bottom">71.7, 82.3, 82.8</td><td align="left" valign="bottom">93.4, 60.5, 159.1</td><td align="left" valign="bottom">142.4, 142.4, 91.3</td><td align="left" valign="bottom">56.4, 144.4, 60.5</td><td align="left" valign="bottom">54.5, 66.3, 142.3</td></tr><tr><td align="left" valign="bottom">α, β, γ (<sup>o</sup>)</td><td align="left" valign="bottom">94.6, 114.1, 111.6</td><td align="left" valign="bottom">90, 101.5, 90</td><td align="left" valign="bottom">90, 101.6, 90</td><td align="left" valign="bottom">95.3, 113.8, 111.5</td><td align="left" valign="bottom">90, 101.2, 90</td><td align="left" valign="bottom">90, 90, 120</td><td align="left" valign="bottom">90, 102.8, 90</td><td align="left" valign="bottom">100.4, 92.3, 91.7</td></tr><tr><td align="left" valign="bottom">Resolution (Å)<xref ref-type="table-fn" rid="table1fn1">*</xref></td><td align="left" valign="bottom">29.48–2.20 (2.25–2.20)</td><td align="left" valign="bottom">29.21–2.54 (2.65–2.54)</td><td align="left" valign="bottom">29.71–1.97(2.02–1.97)</td><td align="left" valign="bottom">29.61–2.67 (2.77–2.67)</td><td align="left" valign="bottom">29.69–2.27 (2.34–2.27)</td><td align="left" valign="bottom">29.55–3.19 (3.30–3.19)</td><td align="left" valign="bottom">29.48–2.68 (2.78–2.68)</td><td align="left" valign="bottom">29.34–2.71 (2.81–2.71)</td></tr><tr><td align="left" valign="bottom">No. molecules in the asymmetric unit (ASU)</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">4</td></tr><tr><td align="left" valign="bottom">No. observations</td><td align="left" valign="bottom">264,344 (16,542)</td><td align="left" valign="bottom">181,285 (21,112)</td><td align="left" valign="bottom">101,891 (4384)</td><td align="left" valign="bottom">155,413 (16,123)</td><td align="left" valign="bottom">471,275 (38,772)</td><td align="left" valign="bottom">693,999 (70,530)</td><td align="left" valign="bottom">184,740 (18,748)</td><td align="left" valign="bottom">552,431 (55,667)</td></tr><tr><td align="left" valign="bottom">No. unique observations</td><td align="left" valign="bottom">75,088 (4440)</td><td align="left" valign="bottom">28,642 (3484)</td><td align="left" valign="bottom">31,038 (1962)</td><td align="left" valign="bottom">43,179 (4542)</td><td align="left" valign="bottom">40,512 (3722)</td><td align="left" valign="bottom">34,411 (3469)</td><td align="left" valign="bottom">26,439 (2627)</td><td align="left" valign="bottom">53,126 (5316)</td></tr><tr><td align="left" valign="bottom">Multiplicity</td><td align="left" valign="bottom">3.5 (3.7)</td><td align="left" valign="bottom">6.3 (6.1)</td><td align="left" valign="bottom">3.3 (2.2)</td><td align="left" valign="bottom">4.7 (1.5)</td><td align="left" valign="bottom">11.6 (10.3)</td><td align="left" valign="bottom">20.1 (20.3)</td><td align="left" valign="bottom">7.0 (7.1)</td><td align="left" valign="bottom">10.4 (10.5)</td></tr><tr><td align="left" valign="bottom">R<sub>merge</sub> (%)<xref ref-type="table-fn" rid="table1fn2">†</xref></td><td align="left" valign="bottom">15.5 (95.2)</td><td align="left" valign="bottom">16.4 (144.5)</td><td align="left" valign="bottom">6.5 (55.7)</td><td align="left" valign="bottom">13.9 (62.8)</td><td align="left" valign="bottom">34.2 (175.0)</td><td align="left" valign="bottom">36.1 (370.6)</td><td align="left" valign="bottom">21.6 (158.6)</td><td align="left" valign="bottom">22.4 (123.5)</td></tr><tr><td align="left" valign="bottom">R<sub>pim</sub> (%) <xref ref-type="table-fn" rid="table1fn3">‡</xref></td><td align="left" valign="bottom">7.5 (32.4)</td><td align="left" valign="bottom">10.6 (97.6)</td><td align="left" valign="bottom">6.1 (46.9)</td><td align="left" valign="bottom">7.8 (30.8)</td><td align="left" valign="bottom">15.3 (83.0)</td><td align="left" valign="bottom">8.2 (84.0)</td><td align="left" valign="bottom">8.8 (63.7)</td><td align="left" valign="bottom">7.3 (39.8)</td></tr><tr><td align="left" valign="bottom">&lt; I/σ I&gt;</td><td align="left" valign="bottom">5.2 (1.5)</td><td align="left" valign="bottom">6.7 (1.5)</td><td align="left" valign="bottom">8.3 (1.5)</td><td align="left" valign="bottom">4.7 (1.5)</td><td align="left" valign="bottom">9.4 (1.5)</td><td align="left" valign="bottom">13.2 (1.7)</td><td align="left" valign="bottom">9.2 (1.6)</td><td align="left" valign="bottom">7.4 (1.6)</td></tr><tr><td align="left" valign="bottom">CC<sub>1/2</sub></td><td align="left" valign="bottom">0.965 (0.527)</td><td align="left" valign="bottom">0.994 (0.529)</td><td align="left" valign="bottom">0.996 (0.603)</td><td align="left" valign="bottom">0.987 (0.669)</td><td align="left" valign="bottom">0.927 (0.435)</td><td align="left" valign="bottom">0.998 (0.756)</td><td align="left" valign="bottom">0.993 (0.578)</td><td align="left" valign="bottom">0.995 (0.729)</td></tr><tr><td align="left" valign="bottom">Completeness (%)</td><td align="left" valign="bottom">97.5 (97.1)</td><td align="left" valign="bottom">99.8 (100.0)</td><td align="left" valign="bottom">98.7 (90.5)</td><td align="left" valign="bottom">98.3 (97.8)</td><td align="left" valign="bottom">99.9 (100.0)</td><td align="left" valign="bottom">99.8 (99.6)</td><td align="left" valign="bottom">99.9 (100.0)</td><td align="left" valign="bottom">100.0 (100.0)</td></tr><tr><td align="left" colspan="9" valign="bottom"><italic>Refinement statistics</italic></td></tr><tr><td align="left" valign="bottom">Reflections used in refinement</td><td align="left" valign="bottom">74,672</td><td align="left" valign="bottom">28,604</td><td align="left" valign="bottom">31,030</td><td align="left" valign="bottom">43,160</td><td align="left" valign="bottom">40,501</td><td align="left" valign="bottom">34,411</td><td align="left" valign="bottom">26,439</td><td align="left" valign="bottom">53,126</td></tr><tr><td align="left" valign="bottom">Reflections used for R-free</td><td align="left" valign="bottom">3731</td><td align="left" valign="bottom">1432</td><td align="left" valign="bottom">1552</td><td align="left" valign="bottom">2162</td><td align="left" valign="bottom">2026</td><td align="left" valign="bottom">1732</td><td align="left" valign="bottom">1314</td><td align="left" valign="bottom">2067</td></tr><tr><td align="left" valign="bottom">Non-hydrogen atoms</td><td align="left" valign="bottom">10,580</td><td align="left" valign="bottom">6872</td><td align="left" valign="bottom">3595</td><td align="left" valign="bottom">10,504</td><td align="left" valign="bottom">6941</td><td align="left" valign="bottom">6818</td><td align="left" valign="bottom">6885</td><td align="left" valign="bottom">13,707</td></tr><tr><td align="left" valign="bottom">Macromolecule</td><td align="left" valign="bottom">10,123</td><td align="left" valign="bottom">6864</td><td align="left" valign="bottom">3418</td><td align="left" valign="bottom">10,344</td><td align="left" valign="bottom">6841</td><td align="left" valign="bottom">6818</td><td align="left" valign="bottom">6845</td><td align="left" valign="bottom">13,620</td></tr><tr><td align="left" valign="bottom">Water</td><td align="left" valign="bottom">433</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">177</td><td align="left" valign="bottom">160</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">34</td><td align="left" valign="bottom">87</td></tr><tr><td align="left" valign="bottom">Heteroatom</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">R <xref ref-type="table-fn" rid="table1fn4">§</xref><sub>work</sub>/R<xref ref-type="table-fn" rid="table1fn5"><sup>¶</sup></xref><sub>free</sub></td><td align="left" valign="bottom">17.9/22.0</td><td align="left" valign="bottom">20.2/24.9</td><td align="left" valign="bottom">18.6/23.5</td><td align="left" valign="bottom">18.6/22.8</td><td align="left" valign="bottom">19.2/23.8</td><td align="left" valign="bottom">18.0/21.0</td><td align="left" valign="bottom">20.7/23.9</td><td align="left" valign="bottom">20.9/24.6</td></tr><tr><td align="left" colspan="9" valign="bottom"><italic>Rms deviations from ideality</italic></td></tr><tr><td align="left" valign="bottom">Bond lengths (Å)</td><td align="left" valign="bottom">0.007</td><td align="left" valign="bottom">0.002</td><td align="left" valign="bottom">0.015</td><td align="left" valign="bottom">0.002</td><td align="left" valign="bottom">0.003</td><td align="left" valign="bottom">0.010</td><td align="left" valign="bottom">0.010</td><td align="left" valign="bottom">0.010</td></tr><tr><td align="left" valign="bottom">Bond angle (°)</td><td align="left" valign="bottom">0.87</td><td align="left" valign="bottom">0.51</td><td align="left" valign="bottom">1.33</td><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">0.71</td><td align="left" valign="bottom">1.39</td><td align="left" valign="bottom">1.25</td><td align="left" valign="bottom">1.22</td></tr><tr><td align="left" colspan="9" valign="bottom"><italic>Ramachandran plot</italic></td></tr><tr><td align="left" valign="bottom">Favored regions (%)</td><td align="left" valign="bottom">97.5</td><td align="left" valign="bottom">97.9</td><td align="left" valign="bottom">97.3</td><td align="left" valign="bottom">97.9</td><td align="left" valign="bottom">98.6</td><td align="left" valign="bottom">94.6</td><td align="left" valign="bottom">97.1</td><td align="left" valign="bottom">97.5</td></tr><tr><td align="left" valign="bottom">Allowed regions (%)</td><td align="left" valign="bottom">2.3</td><td align="left" valign="bottom">2.1</td><td align="left" valign="bottom">2.7</td><td align="left" valign="bottom">1.9</td><td align="left" valign="bottom">1.4</td><td align="left" valign="bottom">5.4</td><td align="left" valign="bottom">2.9</td><td align="left" valign="bottom">2.5</td></tr><tr><td align="left" colspan="9" valign="bottom"><italic>B-factors (A<sup>2</sup></italic>)</td></tr><tr><td align="left" valign="bottom">Wilson B-value</td><td align="left" valign="bottom">39.1</td><td align="left" valign="bottom">64.7</td><td align="left" valign="bottom">35.5</td><td align="left" valign="bottom">47.0</td><td align="left" valign="bottom">50.0</td><td align="left" valign="bottom">91.0</td><td align="left" valign="bottom">42.1</td><td align="left" valign="bottom">54.7</td></tr><tr><td align="left" valign="bottom">Average B-factors</td><td align="left" valign="bottom">45.7</td><td align="left" valign="bottom">75.0</td><td align="left" valign="bottom">45.7</td><td align="left" valign="bottom">51.0</td><td align="left" valign="bottom">53.7</td><td align="left" valign="bottom">111.0</td><td align="left" valign="bottom">71.0</td><td align="left" valign="bottom">77.0</td></tr><tr><td align="left" valign="bottom">Average macromolecule</td><td align="left" valign="bottom">45.7</td><td align="left" valign="bottom">75.9</td><td align="left" valign="bottom">45.9</td><td align="left" valign="bottom">51.1</td><td align="left" valign="bottom">53.7</td><td align="left" valign="bottom">111.0</td><td align="left" valign="bottom">71.4</td><td align="left" valign="bottom">77.2</td></tr><tr><td align="left" valign="bottom">Average heteroatom</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">69.8</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Average water molecule</td><td align="left" valign="bottom">44.0</td><td align="left" valign="bottom">61.4</td><td align="left" valign="bottom">41.1</td><td align="left" valign="bottom">41.9</td><td align="left" valign="bottom">54.3</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">37.8</td><td align="left" valign="bottom">43.3</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>Values in parentheses refer to the highest resolution bin.</p></fn><fn id="table1fn2"><label>†</label><p>R<sub>merge</sub> = ∑hkl ∑i | Ihkl, i -&lt; Ihkl &gt; | / ∑hkl&lt; Ihkl &gt; .</p></fn><fn id="table1fn3"><label>‡</label><p>R<sub>pim</sub> = ∑hkl [1/(N – 1)]1/2 ∑i | Ihkl, i -&lt; Ihkl &gt; | / ∑hkl&lt; Ihkl &gt; .</p></fn><fn id="table1fn4"><label>§</label><p>R<sub>work</sub> = (∑ | |Fo | - |Fc | |) / (∑ | |Fo |).</p></fn><fn id="table1fn5"><label>¶</label><p>5% of data were used for the R<sub>free</sub> calculation.</p></fn></table-wrap-foot></table-wrap><p>The recognition of PvCSPvk210 peptides by 2F2 is mediated mostly by residues localized in heavy chain complementarity-determining regions (HCDRs) 1, 2, and 3, and kappa chain complementarity-determining regions (KCDRs) 1 and 3. The PvCSPvk210 one turn of a 3<sub>10</sub>-helix is positioned in the hydrophobic pocket formed by KCDR1 residues of the antibody (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3C, E, and G</xref>), and is stabilized by three H-bonds formed between A<sub>9</sub> and the backbone of K.Gly91 and K.Phe96, and G<sub>10</sub> and the sidechain of H.Ser58 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). The antibody-antigen complex buries 848 Å<sup>2</sup> on the Fab (437 Å<sup>2</sup> on HC and 411 Å<sup>2</sup> on KC) and 1023 Å<sup>2</sup> on the 210-4 peptide. Peptide residues <sub>1</sub>GRDADG<sub>6</sub> are positioned between HCDR1 and 3 and do not interact with the light chain (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>).</p><p>2F2 binds to PvCSPvk210 peptides using both germline and somatically hypermutated residues. Nine germline-encoded aromatic residues form significant van der Waals interactions with the peptides, contributing a total of ~385 Å<sup>2</sup> of buried surface area (BSA; <xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3C, E, and G</xref>). To accommodate arginine residues present in the sequence of the PvCSPvk210 peptides, the 2F2 paratope has an overall electronegative potential (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4A</xref>). R<sub>3</sub> and Q<sub>7</sub> play a central role in mediating the Fab-peptide interactions, forming six H-bonds with both heavy and light chain residues of the antibody (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), and contributing ~107 Å<sup>2</sup> and ~ 156 Å<sup>2</sup> of BSA, respectively.</p></sec><sec id="s2-3"><title>Molecular basis of mAb 2E10.E9 recognition of the PvCSPvk247 central repeat</title><p>Unlike PvCSPvk210, PvCSPvk247 contains one predominant repeat motif; ‘ANGAGNQPG,’ with the exception of the first (EDGAGNQPG) and the last repeat (ANGAGGQAA) in the central region (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). 2E10.E9 Fab binds peptides derived from PvCSPvk247 with affinity ranging from 0.507 µM (peptide 247-4) to 1.67 µM (peptide 247-1), as measured by ITC. Based on the binding stoichiometry derived from ITC, the 18-aa peptide 247-4 accommodates binding of one Fab, while 27-aa peptides 247-1, 247-2, and 247-3 are long enough to allow two Fabs to bind simultaneously (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>2E10.E9 Fab binding to PvCSPvk247 repeat peptides.</title><p>(<bold>A</bold>) Affinities of 2E10.E9 Fab for peptides 247-1, 247-2, 247-3, and 247-4 as measured by isothermal titration calorimetry (ITC). Open circles represent independent measurements. Mean binding constant (K<sub>D</sub>) and binding stoichiometry (N) values are shown above the corresponding bar. Error bars represent SEM. (<bold>B</bold>) Upper panel: sequences of peptides used in ITC with variable residues underlined. Dark gray denotes the core epitope of the peptide resolved in all X-ray crystal structures, and light gray shading indicates residues resolved in the corresponding X-ray crystal structures. Bottom panel: comparison of the conformations of PvCSP247 peptides in X-ray crystal structures, with peptides 247-2, 247-3, and 247-4 depicted in yellow, orange, and teal, respectively. (<bold>C</bold>) Top and side views of the 247-3 peptide (orange) in the binding groove of the 2E10.E9 Fab shown as surface representation (heavy chain [HC] shown in blue and kappa chain [KC] shown in white). (<bold>D</bold>) Comparison of the conformations adopted by the core epitope of peptides 247-2, 247-3, and 247-4 when bound to 2E10.E9. (<bold>E</bold>) Detailed interactions between Fab 2E10.E9 and peptide 247-3. H-bonds are shown as black dashes, peptide 247-3 is shown in orange, HC is shown in green, and KC is shown in gray. The Fab residues are annotated with H or K letters to indicate heavy and kappa light chain, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Isothermal titration calorimetry (ITC) measurements of 2E10.E9 Fab binding to peptides 247-1 (<bold>A</bold>), 247-2 (<bold>B</bold>), 24-3 (<bold>C</bold>), and 247-4 (<bold>D</bold>).</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Stereo-image of the composite omit map electron density contoured at 1.2 sigma for peptides 247-2 (<bold>A</bold>), 247-3 (<bold>B</bold>), and 247-4 (<bold>C</bold>).</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig4-figsupp2-v2.tif"/></fig></fig-group><p>We obtained co-crystal structures of the 2E10.E9 Fab in complex with three different peptides: 247-3 and 247-4 at ~2.7 Å resolution, and 247-2 at 3.19 Å resolution (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3B, D, and F</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). In the 2E10.E9 Fab-247-2 co-crystal structure, two Fabs bind to one peptide, which is in agreement with the 2:1 stoichiometry established by ITC (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The core epitope of PvCSPvk247 peptides contains eight residues (<sub>3</sub>GAGNQPGA<sub>10</sub>) and adopts a similar coil conformation in all analyzed peptides when bound to 2E10.E9 (peptide backbone RMSD 0.48–1.0 Å), with only isolated turns (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Although 2E10.E9 Fab binds peptides 247-2 and 247-3 containing the first (<underline>ED</underline>GAGNQPG) and the last repeat (ANGAG<underline>G</underline>Q<underline>AA</underline>) motifs, the electron density of residues unique to these repeats was absent in the co-crystal structures obtained. This suggests that the antibody does not interact extensively with these variable residues that are outside the well-resolved conserved core (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><p>2E10.E9 interacts with the PvCSPvk247 peptides using HCDRs 1, 2, and 3, and KCDR1 and 3, with the N-terminal part of the peptide positioned between HCDR1 and 3. Six germline-encoded aromatic residues, including K.Tyr32, K.Tyr92, K.Tyr94, K.Phe96, H.Tyr32, and H.Trp50, play a central role in peptide recognition, forming three H-bonds with G<sub>9</sub>, Ala<sub>10</sub>, and A<sub>13</sub>, and contributing 176 Å<sup>2</sup> BSA to the relatively small paratope of this Fab (444 Å<sup>2</sup> total BSA on the 2E10.E9 paratope; 588 Å<sup>2</sup> total BSA on peptide 247-3) (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3B, D, and F</xref>). Interestingly, HCDR3 H.Cys98 and H.Cys100 make a disulfide bond that positions H.Gly99 in an ideal position to form an H-bond with residue G<sub>9</sub> of the peptide and mimic the stacking effect provided by aromatic sidechains (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Residue N<sub>6</sub> of the PvCSPvk247 peptides is central to the interaction, forming four H-bonds with HCDR2 residues H.Thr30, H.Asn52, and H.Ser52A (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p></sec><sec id="s2-4"><title>Homotypic 2E10.E9 Fab-Fab interactions upon PvCSPvk247 repeat binding</title><p>In the 2E10.E9 Fab-247-2 peptide co-crystal structure where two Fabs bind to one peptide, we observed multiple contacts between the two 2E10.E9 Fabs (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Indeed, the two 2E10.E9 Fabs interact in a head-to-head binding mode at an ~146<sup>o</sup> angle (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Contacts between the two Fabs are mostly symmetric and involve mainly HCDR2 of both Fab A and B, as well as the KCDR3 of Fab A (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). Fab-Fab interactions contribute 949 Å<sup>2</sup> of BSA (482 Å<sup>2</sup> on Fab A, 477 Å<sup>2</sup> on Fab B). The interaction between neighboring 2E10.E9 Fabs is stabilized by five H-bonds; three between HCDR2 residues of both Fab A and B and two additional H-bonds between K.Tyr94 of Fab A, and H.Asn53 and H.Thr73 of Fab B (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Comparison of the 2E10.E9 variable gene sequences to the inferred germline precursor (IGHV9-3 and IGKV8-19) reveals that only one of the residues involved in Fab-Fab contacts has been somatically hypermutated (H.Ser52A), making this homotypic Fab-Fab interaction primarily germline-encoded in the context of binding its repeating epitope (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Homotypic Fab-Fab interactions in Fab 2E10.E9-247-2 peptide complex.</title><p>(<bold>A, B</bold>) 2E10.E9 Fabs that simultaneously recognize the 247-2 peptide contact each other through an interface consisting of mainly of heavy chain complementarity-determining region (HCDR)2 of both Fab A and B, as well as kappa chain complementarity-determining region (KCDR)3 of Fab A. The heavy chain (HC) of Fab A and B is colored light and dark blue, respectively. The kappa chain (KC) of Fab A and B is colored light and dark gray, respectively. HCDR1, 2, and 3 are colored light pink, dark pink, and purple, respectively. KCDR1, 2, and 3 are shown in light brown, dark brown, and red, respectively. The 247-2 peptide is depicted in yellow. Black dashed lines denote H-bonds. Residues forming Fab-Fab contacts are labeled with the position of the Fab (A or B) indicated in subscript. (<bold>C</bold>) Sequence alignment of monoclonal antibody (mAb) 2E10.E9 with its inferred germline precursor. Yellow highlight: residues involved in homotypic interactions; green highlight: residues involved in homotypic interactions that form H-bonds.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig5-v2.tif"/></fig></sec><sec id="s2-5"><title>Central repeat flexibility upon binding of inhibitory antibodies to full-length PvCSP</title><p>Next, we characterized the binding of mAbs 2F2 and 2E10.E9 to full-length recombinant PvCSPvk210 and PvCSPvk247. Both mAbs exhibit fast associations to their respective PvCSP sequences, as revealed in biolayer interferometry (BLI) experiments (<xref ref-type="fig" rid="fig6">Figure 6A and C</xref>). However, mAb 2E10.E9 displays a relatively fast dissociation compared to mAb 2F2, which contributes to the lower overall binding affinity of this mAb to PvCSPvk247 compared to a higher binding affinity for the mAb 2F2-PvCSPvk210 interaction. Next, ITC measurements indicated that, as expected, both 2F2 and 2E10.E9 Fabs bind PvCSP with high stoichiometry indicative of multiple Fab copies interacting with a single PvCSP molecule. 2F2 Fab recognizes PvCSPvk210 with ~10 times higher affinity (0.242 µM) compared to the 2E10.E9 Fab-PvCSPvk247 interaction (2.21 µM), corroborating the binding kinetics data (<xref ref-type="fig" rid="fig6">Figure 6B and D</xref>). Size-exclusion chromatography coupled with multiangle light scattering (SEC-MALS) characterization of the Fab-PvCSP complexes revealed high binding stoichiometry with a molecular weight of ~522 kDa and ~463 kDa for the 2F2 Fab-PvCSPvk210 and 2E10.E9 Fab-PvCSPvk247 complexes, respectively (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). These sizes correspond to approximately 10 2F2 Fab’s bound to one molecule of PvCSPvk210 and to approximately 9 2E10.E9 Fab’s bound to one molecule of PvCSPvk247. Although both ITC and SEC-MALS confirm the assembly of large complexes formed by multiple Fab’s binding to one PvCSP molecule, the exact Fab:PvCSP stoichiometry that ensues from these independent analyses is slightly different between the two techniques, which we attribute to the difficulty in obtaining precise concentration measurements for recombinant PvCSP and to the two experiments being performed at distinct concentrations.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Binding of 2F2 and 2E10.E9 to full-length PvCSPvk210 and PvCSPvk247.</title><p>Binding kinetics of twofold dilutions of 2F2 IgG and Fab (<bold>A</bold>, upper panel and lower panel, respectively) to PvCSPvk210, and 2E10.E9 IgG and Fab (<bold>B</bold>, upper panel and lower panel, respectively) to PvCSPvk247, as measured by biolayer interferometry (BLI). Representative sensograms are shown in black and 2:1 model best fits in red. Data shown are representative of three independent measurements. Isothermal titration calorimetry (ITC) analysis of 2F2 Fab binding to PvCSPvk210 (<bold>C</bold>) and 2E10.E9 Fab binding to PvCSPvk247 (<bold>D</bold>) at 25°C. (<bold>C</bold>, top panels): raw data of PvCSPvk210 (5 µM) in the sample cell titrated with 2F2 Fab (240 µM) in the syringe. (<bold>D</bold>, top panels): raw data of PvCSPvk247 (5 µM) in the sample cell titrated with 2E10.E9 Fab (400 µM) in the syringe. (<bold>C, D</bold>, bottom panel): plot and trendline of heat of injectant corresponding to the raw data. Results from size-exclusion chromatography coupled with multiangle light scattering (SEC-MALS) for the Fab 2F2-PvCSPvk210 sample (<bold>E</bold>, left panel) and 2E10.E9 Fab-PvCSPvk247 (<bold>F</bold>, left panel) sample, where the Fabs are in molar excess. Measurement of the molar mass of the eluting complex is shown as a red line. Mean molar mass is indicated. SDS-PAGE analysis of resulting peaks 1 and 2 for 2F2 Fab-PvCSPvk210 (<bold>E</bold>, right panel) and 2E10.E9 Fab-PvCSPvk247 (<bold>F</bold>, right panel) samples from SEC-MALS. Each peak was sampled in reducing and nonreducing conditions as indicated by + and –, respectively.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>SDS-PAGE analysis of 2F2 Fab-PvCSPvk210 and 2E10.E9 Fab-PvCSPvk247 complexes.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-72908-fig6-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Negative stain electron microscopy (NS EM) and electron cryomicroscopy (cryo-EM) analysis of 2E10.E9 Fab-PvCSPvk247 (<bold>A</bold>) and 2F2 Fab-PvCSPvk210 (<bold>B</bold>) complexes.</title><p>Upper panels show representative NS EM (left panel) and cryo-EM (right panel) micrographs. Positions of representative individual particles are highlighted with white circles. Lower panels: representative NS EM (left panel) and cryo-EM (right panel) 2D class averages. Scale bars on micrographs: 100 nm. Scale bars on 2D classes: 10 nm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig6-figsupp1-v2.tif"/></fig></fig-group><p>To investigate a possible structural ordering of the PvCSP central repeat as might be induced by the binding of multiple 2F2 and 2E10.E9 Fab’s, we performed negative stain electron microscopy (NS EM) and electron cryomicroscopy (cryo-EM) analyses of the SEC-purified Fab-PvCSP complexes (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). 2D class average images from the negative stain micrographs of the 2E10.E9 Fab-PvCSPvk247 complex revealed multiple 2E10.E9 Fabs spaced tightly against each other (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>, left panels). However, cryo-EM analysis of the same 2E10.E9 Fab-PvCSPvk247 complex indicated that Fab 2E10.E9 does not form regular, spiral assemblies with CSP, presumably because this type of complex would not accommodate the symmetric, head-to-head interactions between 2E10.E9 Fabs that were observed in the 2E10.E9 Fab-247-2 peptide crystal structure (<xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>, right panels).</p><p>Interestingly, 2D classes from the negative stain micrographs of the 2F2 Fab-PvCSPvk210 complex indicated multiple conformational states, and thereby suggest that the PvCSPvk210 central repeat region remains largely flexible upon binding by 2F2 Fabs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>, left panels). Cryo-EM analysis of the same 2F2 Fab-PvCSPvk247 complex showed similar conformational heterogeneity (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>, right panels). These results suggest that the 2F2 Fabs may not be stabilized by appreciable inter-Fab contacts as observed for 2E10.E9 Fabs. To gain a better understating of the conformational flexibility observed for the 2F2 Fab-PvCSPvk210 complex, we collected NS EM data of the 2F2 Fab bound to a PvCSPvk210-derived peptide of sufficient length to accommodate binding of two Fabs (peptide 210-10, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). EM class averages from the micrographs of the 2F2 Fab-210-10 peptide complex displayed high variability in the angles between the two Fabs, ranging from ~30° to ~170° (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). These data indicate that the complex is highly flexible, and that the two Fabs are likely not forming extensive stabilizing inter-Fab homotypic contacts upon binding the repeat peptide. This mode of binding is in contrast to other Fab-peptide complexes known to form extensive homotypic interactions (2E10.E9 Fab-247-2 [<xref ref-type="fig" rid="fig7">Figure 7B</xref>], 3D11 Fab-NPNDx2 [<xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>; <xref ref-type="fig" rid="fig7">Figure 7C</xref>], and 1210 Fab-NANP<sub>5</sub> [<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>; <xref ref-type="fig" rid="fig7">Figure 7D</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>]). Complexes that form homotypic contacts showed lower flexibility than the 2F2 Fab-210-10 peptide complex, with either one or two distinct 3D classes present.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Evaluation of flexibility for various Fab-CSP peptide complexes by negative stain electron microscopy.</title><p>Refined 3D classes (upper panels) and representative 2D class averages (bottom panels) of (<bold>A</bold>) 2F2 Fab-210-10 peptide, (<bold>B</bold>) 2E10.E9 Fab-247-2 peptide, (<bold>C</bold>) 3D11 Fab-NPNDx2 peptide (PPPPNPND)<sub>3</sub> (<xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>), and (<bold>D</bold>) 1210 Fab-(NANP)<sub>5</sub> peptide (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>) complexes. The approximate angle between adjacent Fabs in each class is indicated. Scale bars on 3D and 2D classes: 50 nm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72908-fig7-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Previous knowledge of inhibitory mAbs against the PfCSP repeats suggest that an in-depth molecular understanding of PvCSP could facilitate the design of next-generation Pv biomedical interventions. Indeed, molecular characterization of hundreds of human mAbs induced either by natural infection (<xref ref-type="bibr" rid="bib84">Triller et al., 2017</xref>), Pf sporozoite immunization (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib55">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib81">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib85">Wang et al., 2020</xref>), or RTS,S/AS01 vaccination (<xref ref-type="bibr" rid="bib59">Oyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>) revealed important insights into vaccine design and antibodies as prophylactics. These include preferential mAb binding to the conserved core epitope (N/D)PNANPN(V/A) (<xref ref-type="bibr" rid="bib55">Murugan et al., 2020</xref>) and potential correlations of protection with binding affinity and recognition of epitopes with secondary structural motifs of type I β- and pseudo 3<sub>10</sub>-turns (<xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>). Moreover, a subset of potent mAbs elicited by whole sporozoite vaccination was shown to not only bind to NANP repeats, but also to a junctional epitope positioned between the N terminus and the central repeat domain of PfCSP, which is absent in the RTS,S vaccine (<xref ref-type="bibr" rid="bib39">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib85">Wang et al., 2020</xref>). Our understanding of CSP targeting by neutralizing mAbs is however almost exclusively limited to PfCSP. Despite the prominence of Pv malaria morbidity worldwide, a molecular understanding of PvCSP and how its central repeat is recognized by inhibitory antibodies has remained scarce.</p><p>Here, we performed CD spectroscopy and MD simulations on PvCSP repeat peptides to better understand the unliganded structure of this inhibitory antibody target. Our data show that all analyzed peptides are disordered in solution and any secondary structure observed is local and transient. This result is similar to what has been previously described for the Pf and Pb CSP repeat region (<xref ref-type="bibr" rid="bib21">Dyson et al., 1990</xref>; <xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>). Interestingly, the sequence composition of the CSP repeats from these three <italic>Plasmodium</italic> species is substantially different; whereas PfCSP and PbCSP are asparagine and proline-rich, PvCSP is predominantly alanine and glycine-rich. In addition, the repeating modulus for PfCSP and PbCSP contains four amino acids, whereas the repeating modulus of PvCSP contains nine amino acids. These comparisons underscore a diversity of amino acid features associated with low structural propensity in repeating sequences.</p><p>Interestingly, calculations of elastic modulus demonstrated that PvCSP peptides behave like harmonic springs, meaning that the stretching or compressing of the peptides is proportional to the force applied to them. Elastic properties are well characterized in a vast array of proteins of different functions, including elastin, spider silk, or mussel byssus (<xref ref-type="bibr" rid="bib28">Gosline et al., 2002</xref>). The high degree of conformational disorder and the resulting elastic properties of PvCSP peptides likely stem from the combination of the low complexity periodic nature of the sequence as well as the particular amino acid composition of this region. A high combined proline and glycine content was shown to distinguish the sequence of self-assembled elastomeric proteins such as elastin, resilin, and elastic spider silks, amongst many others, from that of proteins prone to amyloid formation (<xref ref-type="bibr" rid="bib70">Rauscher et al., 2006</xref>). Both proline and glycine are ‘amyloid breakers’ because of their low propensity to form regular secondary structure such as the extended β-sheets found at the core of amyloid fibrils (<xref ref-type="bibr" rid="bib63">Parrini et al., 2005</xref>; <xref ref-type="bibr" rid="bib86">Williams et al., 2004</xref>). As such, a high proline and glycine content enables self-assembled elastomers to avoid the amyloid fate while remaining disordered even in the assembled or phase-separated state. In turn, high structural disorder enables these proteins to function as entropic springs, whereby the large conformational entropy of the polypeptide chain provides at least part of the driving force for elastic recoil. PvCSP peptides have glycine and proline contents of ~22–33% and ~7–11%, respectively, and thus are predicted to fall within the transition region separating amyloidogenic from elastomeric proteins, the latter of which include elastin domains and insect resilin (<xref ref-type="bibr" rid="bib70">Rauscher et al., 2006</xref>). Moreover, the elastic modulus of PvCSP peptides (~3–5 cal/(mol Å<sup>2</sup>)) is commensurate with the elastic modulus of peptides modeled after human elastin (~9 cal/(mol Å<sup>2</sup>)), which requires extensibility and elasticity for its physiological function (<xref ref-type="bibr" rid="bib71">Reichheld et al., 2021</xref>). This analogy supports the observation that CSP is inherently elastic and suggests that achieving a high degree of conformational disorder may be an essential aspect of CSP function on the surface of sporozoites. Interestingly, recent in vitro experiments demonstrated that PbCSP repeats also have elastic properties, which are lost when the repeat sequence is scrambled (<xref ref-type="bibr" rid="bib6">Balaban et al., 2021</xref>). The link between the elasticity of CSP repeats and CSP function is still not completely understood; yet, it appears that biophysical properties of the CSP repeats are necessary for maintaining sporozoite motility (<xref ref-type="bibr" rid="bib6">Balaban et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Coppi et al., 2011</xref>), even though CSP itself is not a motor protein.</p><p>The presence of disorder in all analyzed PvCSP repeat peptide structures was also appreciated in our X-ray crystallography data, where inhibitory mAbs 2F2 and 2E10.E9 were found to recognize their epitopes in an induced coil conformation, with only one turn of a 3<sub>10</sub>-helix and isolated turns as secondary structure motifs observed in both instances. Binding of the CSP repeat by inhibitory antibodies has been shown to induce a range of conformations in this intrinsically disordered region for Pf and Pb<italic>,</italic> with the occasional presence of type I β-turns and pseudo 3<sub>10</sub>-turns often but not always linked with antibody-mediated protection (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Oyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib65">Pholcharee et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>; <xref ref-type="bibr" rid="bib75">Scally and Julien, 2018</xref>; <xref ref-type="bibr" rid="bib81">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib84">Triller et al., 2017</xref>).</p><p>PfCSP- and PbCSP-reactive antibodies have been shown to cross-react to a varying extent with the predominant repeat motif and neighboring sequences of subtle variance within the repeat region, for example, the PfCSP junction (<xref ref-type="bibr" rid="bib35">Julien and Wardemann, 2019</xref>; <xref ref-type="bibr" rid="bib39">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib55">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib76">Scally et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Tan et al., 2018</xref>). Cross-reactivity is a feature of human antibodies encoded by various Ig-gene combinations and was also observed in murine antibodies against the PfCSP repeat (mAb 2A10; <xref ref-type="bibr" rid="bib90">Zavala et al., 1983</xref>) and against the PbCSP repeat (3D11; <xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>; <xref ref-type="bibr" rid="bib89">Yoshida et al., 1980</xref>). Our data indicate that both mAbs 2F2 and 2E10.E9 are cross-reactive as they bind to different repeat motifs of their respective PvCSP variants with similar affinity and in identical conformations. mAbs 2F2 and 2E10.E9 are, however, not cross-reactive to different strains of Pv (<xref ref-type="bibr" rid="bib57">Nardin et al., 1982</xref>) due to the significantly different CSP sequences of strains PvCSPvk210 and PvCSPvk247. Although both mAbs 2F2 and 2E10.E9 are inhibitory, only mAb 2F2 was reported to induce aberrations in size and in DNA content of sporozoites, indicating a distinct mechanism of attenuation (<xref ref-type="bibr" rid="bib74">Roth et al., 2018</xref>), possibly due to the higher affinity to PvCSP and slower dissociation rate of mAb 2F2 compared to mAb 2E10.E9.</p><p>Both mAbs 2F2 and 2E10.E9 recognize their respective epitopes using germline-encoded and somatically hypermutated residues. The difference in affinities between mAbs 2E10.E9 and 2F2 and their respective antigen might partially stem from the low lumber of somatic hypermutations of mAb 2E10.E9 (1 in HC, 6 in KC) compared to 2F2 (14 in HC, 4 in KC). Specifically, mAbs 2F2 and 2E10.E9 use nine and six germline-encoded aromatic residues, respectively, to mediate contacts with their core epitopes. Germline-encoded mAb 2E10.E9 residue H.Trp50 forms extensive van der Waals interactions with N<sub>6</sub> and P<sub>8</sub> residues, analogous to <italic>IGHV3-33</italic> germline-encoded H.Trp52 in several human mAbs, including mAbs MGG4 (<xref ref-type="bibr" rid="bib81">Tan et al., 2018</xref>), 1210 (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>), 311 (<xref ref-type="bibr" rid="bib59">Oyen et al., 2017</xref>), and other antibodies induced by sporozoite immunization (<xref ref-type="bibr" rid="bib55">Murugan et al., 2020</xref>) or RTS,S vaccination (<xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>; <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3D and F</xref>). As both human and murine mAbs appear to depend on germline-encoded aromatic residues for CSP recognition, it is likely that CSP repeats prime the mammalian immune system to select antibodies from germline genes with already optimally positioned aromatic residues.</p><p>MAb 2E10.E9 displays homotypic Fab-Fab interactions, as was previously described for mAbs 1210 (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>), 311 (<xref ref-type="bibr" rid="bib60">Oyen et al., 2018</xref>), and 239 and 399 (<xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>) against PfCSP and murine mAb 3D11 against PbCSP (<xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>). 2E10.E9 Fabs interact in a head-to-head binding mode, forming symmetric interactions similar to those observed in the case of antibodies 1210 (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>) and 399 (<xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>). Interestingly, mAb 2E10.E9 does not appear to bind longer PvCSPvk247 peptides with higher affinity compared to shorter PvCSPvk247 peptides (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), in contrast to what has been described for other mAbs that recognize the PfCSP and PbCSP repeats and form homotypic interactions (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>). Unlike mAbs 1210 (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>) and 3D11 (<xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>), the residues forming Fab-Fab contacts in mAb 2E10.E9 are almost exclusively germline-encoded, similar to mAb 399 (<xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>). Combined, these results suggest that forming Fab-Fab interactions is ubiquitous among anti-CSP mAbs targeting different <italic>Plasmodium</italic> species. Analysis of human mAbs isolated after immunization with whole Pf sporozoites indicated that NANP homotypic antibody interactions promote activation and strong clonal expansion of PfCSP-reactive B-cells (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>). It appears that homotypic interactions may emerge from B-cell receptor clustering on the surface of B cells (<xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>); however, a direct link between homotypic interactions in the context of soluble antibodies and sporozoite inhibition is still to be established. mAbs 2F2 and 2E10.E9 recognize core PvCSP epitopes of 10 and 8 residues, respectively. Interestingly, potent inhibitory mAbs against PfCSP and PbCSP typically recognize epitopes of similar length (8–10 residues; <xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Pholcharee et al., 2021</xref>), despite shorter repeating motifs for PfCSP and PbCSP (4-aa) compared to PvCSP (9-aa). Given the similar antibody epitope lengths, in addition to similar structural propensities for underlying antigenic motifs and induction of antibody homotypic interactions when recognizing closely spaced repeating epitopes, we suggest that similar CSP-based vaccine design approaches could be applied across different <italic>Plasmodium</italic> species. Nevertheless, the lack of <italic>Plasmodium</italic> species cross-reactivity for the potent inhibitory mAbs described thus far suggests that different pre-erythrocytic vaccines or a multicomponent CSP-based vaccine will likely be required for broad coverage against the different <italic>Plasmodium</italic> species causative of human malaria morbidity and mortality worldwide.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.4-2F2 <break/>Fab HC (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">2F2 Fab heavy chain gene in pcDNA3.4 TOPO vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.4-2F2 <break/>KC (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">2F2 light chain gene in pcDNA3.4 TOPO vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.4-2E10.E9 <break/>Fab HC (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">2E10.E9 Fab heavy chain gene in pcDNA3.4 TOPO vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.4-2E10.E9 <break/>KC (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">2E10.E9 light chain gene in pcDNA3.4 TOPO vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.4-<break/>PvCSPvk210-<break/>His6x (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">PvCSPvk210 gene with His tag in pcDNA3.4 TOPO vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.4- <break/>PvCSPvk247-<break/>His6x (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">PvCSPvk247 gene with His tag in pcDNA3.4 TOPO vector</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">FreeStyle <break/>293F cells</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# R79007</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">2F2 <break/>hybridoma cell line</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib57">Nardin et al., 1982</xref>, Alan Cochrane, unpublished results</td><td align="left" valign="bottom">BEI Resources #MRA-184; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_A7VR">CVCL_A7VR</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">2E10.E9 <break/>hybridoma cell line</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib57">Nardin et al., 1982</xref>, Alan Cochrane, unpublished results</td><td align="left" valign="bottom">BEI Resources #MRA-185; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_A7VT">CVCL_A7VT</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gibco FreeStyle <break/>293 Expression <break/>Medium</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12338026</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gibco <break/>Hybridoma-SFM</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12045076</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FectoPRO DNA <break/>Transfection <break/>Reagent</td><td align="left" valign="bottom">VWR</td><td align="left" valign="bottom">Cat# 10118-444</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fetal bovine <break/>serum</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12483-020</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">2F2 IgG <break/>(mouse <break/>monoclonal)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib57">Nardin et al., 1982</xref>, Alan Cochrane, unpublished results</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Purified from 2F2 hybridoma cell line; see Materials and methods</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">2E10.E9 IgG <break/>(mouse <break/>monoclonal)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib57">Nardin et al., 1982</xref>, Alan Cochrane, unpublished results</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Purified from 2E10.E9 hybridoma cell line; see Materials and methods</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Carica papaya</italic>)</td><td align="left" valign="bottom">Papain from <break/>papaya latex</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# P4762</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="char" char="." valign="bottom">1210 Fab</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">See Materials and methods for concentrations and masses used, and buffer conditions</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="char" char="." valign="bottom">3D11 Fab</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">See Materials and methods for concentrations and masses used, and buffer conditions</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="char" char="." valign="bottom">2F2 Fab</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">See Materials and methods for concentrations and masses used, and buffer conditions</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="char" char="." valign="bottom">2E10.E9 Fab</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">See Materials and methods for concentrations and masses used, and buffer conditions</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-1 <break/>(GDRADGQ<break/>PAGDRADGQPA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-2 <break/>(GDRAAGQ<break/>PAGDRAAGQPA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-3 <break/>(GDRADGQP<break/>AGDRAAGQPA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-4 <break/>(GDRAAGQ<break/>PAGDRADGQP)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-5 <break/>(GDRAAGQ<break/>PAGNGAGGQAA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-6 <break/>(GDRADGQ<break/>PAGDRADGQ<break/>PAGDRADGQPA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-7 <break/>(GDRAAGQ<break/>PAGDRAAGQ<break/>PAGDRAAGQPA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-8 <break/>(GDRADGQ<break/>PAGDRAAGQ<break/>PAGDRADGQPA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-9 <break/>(GDRAAGQ<break/>PAGDRAAGQ<break/>PAGNGAGGQAA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">210-10 <break/>(GDRADGQ<break/>PAGDRADGQ<break/>PAGDRADGQ<break/>PAGDRADGQPA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk210 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">247-1 <break/>(ANGAGNQ<break/>PGANGAGNQ<break/>PGANGAGNQPG)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk247 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">247-2 <break/>(EDGAGNQ<break/>PGANGAGNQ<break/>PGANGAGNQPG)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk247 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">247-3 <break/>(ANGAGNQ<break/>PGANGAGNQ<break/>PGANGAGGQAA)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk247 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">247-4 <break/>(ANGAGNQ<break/>PGANGAGNQPG)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PvCSPvk247 repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">NPNDx2 <break/>(PPPPNPNDP<break/>PPPNPNDP<break/>PPPNPND)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib42">Kucharska et al., 2020</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PbCSP ANKA repeat region</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">NANP<sub>5</sub> <break/>(NANPNAN<break/>PNANPNA<break/>NPNANP)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib33">Imkeller et al., 2018</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Derived from PfCSP NF54 repeat region</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GROMACS 2016.5</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Berendsen et al., 1995</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://manual.gromacs.org/documentation/2016-current/index.html">https://manual.gromacs.org/documentation/2016-current/index.html</ext-link>;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014565">SCR_014565</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CHARMM22*</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib10">Best and Hummer, 2009</xref>; <xref ref-type="bibr" rid="bib11">Best and Mittal, 2010</xref>; <xref ref-type="bibr" rid="bib43">Lindorff-Larsen et al., 2012</xref>; <xref ref-type="bibr" rid="bib45">MacKerell et al., 1998</xref>; <xref ref-type="bibr" rid="bib67">Piana et al., 2011</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.charmm.org/charmm/?CFID=66837e22-4ee5-47ba-bcbf-b4b385c2397e&amp;CFTOKEN=0;">https://www.charmm.org/charmm/?CFID=66837e22-4ee5-47ba-bcbf-b4b385c2397e&amp;CFTOKEN=0;</ext-link> RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014892">SCR_014892</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">LINCS</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib30">Hess, 2008</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Particle-Mesh <break/>Ewald algorithm</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Darden et al., 1993</xref>; <xref ref-type="bibr" rid="bib23">Essmann et al., 1995</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Parrinello–Rahman algorithm</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib62">Parrinello and Rahman, 1981</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">VMD</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Humphrey et al., 1996</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.ks.uiuc.edu/Research/vmd/">https://www.ks.uiuc.edu/Research/vmd/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_001820">SCR_001820</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Matplotlib</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Hunter, 2007</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://matplotlib.org/">https://matplotlib.org/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008624">SCR_008624</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MDTraj</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib48">McGibbon et al., 2015</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.mdtraj.org/1.9.5/index.html">https://www.mdtraj.org/1.9.5/index.html</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Octet Data AnalysisSoftware 9.0.0.6</td><td align="left" valign="bottom">ForteBio</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.fortebio.com/products/octet-systems-software">https://www.fortebio.com/products/octet-systems-software</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MicroCal ITC Origin7.0 Analysis Software</td><td align="left" valign="bottom">Malvern</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.malvernpanalytical.com/">https://www.malvernpanalytical.com/</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ASTRA</td><td align="left" valign="bottom">Wyatt</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.wyatt.com/products/software/astra.html">https://www.wyatt.com/products/software/astra.html</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016255">SCR_016255</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 8</td><td align="left" valign="bottom">GraphPad Software</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SBGrid</td><td align="left" valign="bottom">SBGrid Consortium</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://sbgrid.org/">https://sbgrid.org/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003511">SCR_003511</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">cryoSPARC v2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib69">Punjani et al., 2017</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cryosparc.com/">https://cryosparc.com/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016501">SCR_016501</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Relion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib77">Scheres, 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www3.mrc-lmb.cam.ac.uk/relion/">https://www3.mrc-lmb.cam.ac.uk/relion/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016274">SCR_016274</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">XDS</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Kabsch, 2010</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://xds.mpimf-heidelberg.mpg.de/">http://xds.mpimf-heidelberg.mpg.de/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015652">SCR_015652</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Phaser</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">McCoy et al., 2007</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.phenix-online.org/">https://www.phenix-online.org/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014224">SCR_014224</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Phenix (phenix.<break/>refine; phenix.real_<break/>space_refine)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Adams et al., 2010</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.phenix-online.org/">https://www.phenix-online.org/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014224">SCR_014224</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">UCSF Chimera</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib64">Pettersen et al., 2004</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.cgl.ucsf.edu/chimera/">https://www.cgl.ucsf.edu/chimera/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_004097">SCR_004097</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">UCSF ChimeraX</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib26">Goddard et al., 2018</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.cgl.ucsf.edu/chimerax/">https://www.cgl.ucsf.edu/chimerax/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015872">SCR_015872</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Coot</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib22">Emsley et al., 2010</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/">https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014222">SCR_014222</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PyMOL</td><td align="left" valign="bottom">The PyMOL Molecular Graphics System, version 1.8 Schrödinger, LLC.</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/#products">https://pymol.org/2/#products</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_000305">SCR_000305</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PDBePISA</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib40">Krissinel and Henrick, 2007</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/pdbe/pisa/">https://www.ebi.ac.uk/pdbe/pisa/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015749">SCR_015749</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Stride</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib29">Heinig and Frishman, 2004</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://webclu.bio.wzw.tum.de/stride/">http://webclu.bio.wzw.tum.de/stride/</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Homemade <break/>holey gold grids</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Marr et al., 2014</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Homemade <break/>carbon grids</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib12">Booth et al., 2011</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"> </td></tr></tbody></table></table-wrap><sec id="s4-1"><title>CD spectroscopy</title><p>The lyophilized samples of peptides 210-1, 210-2, 210-3, 210-4, 210-5, 247-1, 247-2, and 247-3 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) were suspended in pH 7.4 PBS buffer and diluted to 0.1 mg/mL. Spectra were collected using a Jasco J-1500 Spectropolarimeter with a cuvette path length of 0.1 cm, 2 s response time, 1 nm bandwidth, and a 100 nm/min scanning speed. Three spectra were collected at room temperature for each peptide.</p></sec><sec id="s4-2"><title>MD simulations</title><p>GROMACS 2016.5 (<xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Berendsen et al., 1995</xref>) was used to perform all-atom molecular simulations of the following seven peptides: 210-6, 210-7, 210-8, 210-9, 247-1, 247-2, and 247-3 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). The CHARMM22* (<xref ref-type="bibr" rid="bib10">Best and Hummer, 2009</xref>; <xref ref-type="bibr" rid="bib11">Best and Mittal, 2010</xref>; <xref ref-type="bibr" rid="bib43">Lindorff-Larsen et al., 2012</xref>; <xref ref-type="bibr" rid="bib45">MacKerell et al., 1998</xref>; <xref ref-type="bibr" rid="bib67">Piana et al., 2011</xref>) force field and the CHARMM-modified TIP3P (TIPS3P) explicit water model (<xref ref-type="bibr" rid="bib34">Jorgensen et al., 1983</xref>) were used for all simulations. PyMOL (<xref ref-type="bibr" rid="bib78">Schrödinger, 2015</xref>) was used to design the peptides with acetylated N-terminus and amidated C-terminus. The peptides were first collapsed from their arbitrary extended state without any solvent (in vacuo) under NVT conditions. The last conformations from simulations in vacuo were used to initiate equilibrium simulations in water, with 20 replicas for each peptide.</p><p>Peptides were solvated with water and 0.15 M NaCl in a rhombic dodecahedral box, with a side length of 4.0 nm. Periodic boundary conditions were applied, and energy minimization was carried out using the steepest descent algorithm. Lennard–Jones and short-range electrostatic interactions were computed with a cutoff of 9.5 Å. Long-range electrostatic interactions were computed with Particle-Mesh Ewald summation (<xref ref-type="bibr" rid="bib19">Darden et al., 1993</xref>; <xref ref-type="bibr" rid="bib23">Essmann et al., 1995</xref>), using a fourth-order interpolation and a grid spacing of 1.2 Å. All bonds were constrained using the LINCS algorithm (<xref ref-type="bibr" rid="bib30">Hess, 2008</xref>). The system was brought to the specified temperature of 300 K and pressure of 1 atm under NPT conditions. 10 ns NPT simulations were performed with velocity-rescaling temperature coupling (<xref ref-type="bibr" rid="bib13">Bussi et al., 2007</xref>) and Berendsen pressure coupling (<xref ref-type="bibr" rid="bib8">Berendsen et al., 1984</xref>). Finally, simulations were carried out under NPT conditions with Parrinello–Rahman pressure coupling (<xref ref-type="bibr" rid="bib62">Parrinello and Rahman, 1981</xref>) for 300 ns. The integration step was 2 fs, and atomic coordinates were recorded every 100 ps.</p></sec><sec id="s4-3"><title>MD simulation analyses</title><p>Visual molecular dynamics (VMD) (<xref ref-type="bibr" rid="bib31">Humphrey et al., 1996</xref>) was used to create snapshots of peptides, while all plots were created with Matplotlib (<xref ref-type="bibr" rid="bib32">Hunter, 2007</xref>). The first 225 ns were excluded for computation of secondary structure propensities per residue, as well as for H-bonding contact maps. Secondary structure was assigned using the Python package MDTraj (<xref ref-type="bibr" rid="bib48">McGibbon et al., 2015</xref>), which uses the DSSP algorithm (<xref ref-type="bibr" rid="bib56">Nagy and Oostenbrink, 2014</xref>). An in-house script was used to compute H-bonding contact maps. Forward peptide-peptide H-bonds form between C=O of residue <italic>i</italic> and N–H of residue <italic>i + n</italic>. A forward H-bond was identified if the donor-acceptor distance (r<sub>ON</sub>) and the hydrogen-donor-acceptor angle (θ) were less than 3.5 Å and 37<bold>°</bold> for n = 2 (γ-turn), 4.9 Å and 66<bold>°</bold> for n = 3 (β-turns), 4.5 Å and 60<bold>°</bold> for n = 4 (α-turn) and 3.5 Å and 40<bold>°</bold> for n ≥ 5. A reverse turn is formed between N–H of residue <italic>i</italic> and C=O of residue <italic>i + n</italic>, and identified if r<sub>ON</sub> &lt; 3.5 Å and <italic>θ</italic> &lt; 60<bold>°</bold> (except for n = 3, for which <italic>θ</italic> &lt; 40<bold>°</bold>). From a histogram of equilibrium end-to-end distances (<italic>d</italic> = distance between Cα of the first and last residues), the probabilities at each given <italic>d</italic> (<italic>P</italic>(<italic>d</italic>)) were used to compute a free energy profile (Δ<italic>G</italic>(<italic>d</italic>)) of the peptide’s end-to-end distances. The resulting potential of mean force (PMF) was then fitted to the quadratic function of elastic potential energy:<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>B</mml:mi><mml:mi>T</mml:mi><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≅</mml:mo><mml:mrow><mml:mo>½</mml:mo></mml:mrow><mml:mi>k</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></disp-formula></p><p>where <italic>k<sub>B</sub></italic> is the Boltzmann constant, <italic>T</italic> is the absolute temperature, <italic>k</italic> represents the stiffness or elastic modulus of the peptide, and <italic>d</italic><sub>0</sub> is the equilibrium end-to-end distance.</p></sec><sec id="s4-4"><title>2F2 and 2E10.E9 IgG expression and purification</title><p>Hybridoma cell lines for mAbs 2F2 and 2E10.E9 (BEI Resources MRA-184 and MRA-185, respectively) were cultured in Gibco Hybridoma-SFM (Thermo Fisher Scientific Cat#12045076) with 5–20% fetal bovine serum (Thermo Fisher Scientific Cat# 12483-020). After 5–7 days, cells were harvested and centrifuged. The supernatant containing 2F2 or 2E10.E9 IgG was purified via Protein G affinity chromatography (GE Healthcare) and size-exclusion chromatography (Superose 6 Increase 10/300 GL, GE Healthcare).</p></sec><sec id="s4-5"><title>2E10.E9 IgG papain digestion</title><p>To obtain Fab, 2E10.E9 IgG was digested with papain (Sigma-Aldrich Cat#P4762) at a 5:1 molar ratio for 16 h at 37°C in PBS, 10 mM EDTA, 20 mM cysteine, pH 7.4. Fc, and non-digested IgG were removed via Protein A affinity chromatography (GE Healthcare). 2E10.E9 Fab was subsequently purified via size-exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare), concentrated, and diluted to 10 mg/mL with peptide 247-4 to immediately use in crystallization experiments.</p></sec><sec id="s4-6"><title>2F2 Fab and 2E10.E9 Fab expression and purification</title><p>Variable light and heavy chains of mAb 2F2 and 2E10.E9 antibody genes were sequenced from the hybridomas (BEI Resources MRA-184 and MRA-185, respectively; Applied Biological Materials Inc). Sequenced regions were gene synthesized and cloned (GeneArt) into custom pcDNA3.4 expression vectors immediately upstream of human Igκ and Igγ1-C<sub>H</sub>1 domains. pcDNA3.4-Fab KC and Fab HC plasmids were co-transfected into HEK 293F cells for transient expression using FectoPRO DNA transfection reagent (Polyplus). Cells were cultured in Gibco FreeStyle 293 Expression Medium for 6–7 days and subsequently purified via a combination of KappaSelect affinity chromatography (GE Healthcare), cation exchange chromatography (MonoS, GE Healthcare), and size-exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare).</p></sec><sec id="s4-7"><title>Recombinant PvCSP expression and purification</title><p>Constructs of full-length PvCSPvk210 (GenBank accession number: AAA29526.1) and PvCSPvk247 (GenBank accession number: AAA29506.1) were gene synthesized and cloned (GeneArt) into pcDNA3.4 expression vectors with a His<sub>6x</sub> tag. The resulting pcDNA3.4-PvCSPvk210-His<sub>6x</sub> and pcDNA3.4-PvCSPvk247-His<sub>6x</sub> plasmids were transiently transfected in HEK 293F cells using FectoPRO DNA transfection reagent (Polyplus), cultured in Gibco FreeStyle 293 Expression Medium, and purified by HisTrap FF affinity chromatography (GE Healthcare) and size-exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare).</p></sec><sec id="s4-8"><title>Cell lines</title><p>HEK 293F cells (Thermo Fisher Scientific 12338026) and mAb 2F2 and 2E10.E9 hybridoma cell lines (BEI Resources MRA-184 and -185, respectively) were authenticated and validated to be mycoplasma-free by their respective commercial entities.</p></sec><sec id="s4-9"><title>Biolayer interferometry</title><p>BLI (Octet RED96, ForteBio) experiments were conducted to determine the binding kinetics of 2F2 and 2E10.E9 IgG and Fab to recombinant PvCSPvk210 and PvCSPvk247. PvCSPvk210 or PvCSPvk247 was diluted to 10 µg/mL in kinetics buffer (PBS, pH 7.4, 0.01% [w/v] BSA, 0.002% [v/v] Tween-20) and immobilized onto Ni-NTA biosensors (ForteBio). Subsequently, biosensors were dipped into wells containing dilutions of either 2F2 or 2E10.E9 IgG or Fab in kinetics buffer. For measurement of the dissociation rate, tips were immersed back into kinetics buffer after association. All data were analyzed using ForteBio’s Octet Data Analysis software 9.0.0.6, and curves were fitted to a 2:1 binding model given the presence of multiple epitopes of slightly different sequence composition for these mAbs within a single PvCSP molecule.</p></sec><sec id="s4-10"><title>Isothermal titration calorimetry</title><p>ITC experiments were performed with an Auto-iTC200 instrument (Malvern) at 25°C. Titrations were performed with 2F2 or 2E10.E9 Fab in the syringe in 15 successive injections of 2.5 µl. Full-length recombinant PvCSPvk210 and PvCSPvk247, and PvCSP-derived peptides (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) were added to the calorimetric cell. All proteins and peptides were diluted in Tris-buffered saline (TBS; 20 mM Tris pH 8.0, and 150 mM NaCl). Full-length recombinant PvCSP was diluted to 5 µM and titrated with Fab at 240–400 µM. All PvCSP-derived peptides were diluted to 4–8 µM and titrated with 2F2 Fab at 100–125 µM or 2E10.E9 Fab at 180–220 µM. Experiments were performed at least in duplicates, and the mean and standard error of the mean are reported. ITC data were analyzed using the Micro-Cal ITC Origin 7.0 Analysis Software according to a 1:1 binding model.</p></sec><sec id="s4-11"><title>Size-exclusion chromatography-multiangle light scattering</title><p>Full-length recombinant PvCSPvk210 or PvCSPvk247 was complexed with a molar excess of 2F2 or 2E10.E9 Fab and loaded on a Superose 6 Increase 10/300 GL column (GE Healthcare) using an Agilent Technologies 1260 Infinity II HPLC coupled inline with the following calibrated detectors: (i) MiniDawn Treos MALS detector (Wyatt); (ii) quasi elastic light scattering (QELS) detector (Wyatt); and (iii) Optilab TreX refractive index (RI) detector (Wyatt). Data processing was performed using the ASTRA software (Wyatt).</p></sec><sec id="s4-12"><title>Crystallization and structure determination</title><p>Purified 2F2 Fab was concentrated and diluted to 5 mg/mL with peptides 210-1, 210-2, 210-3, 210-4, and 210-5 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) in a 1:3 molar ratio. The 2F2 Fab-peptide complexes were mixed in a 1:1 ratio with the following conditions to obtain crystals: 0.2 M ammonium sulfate, 25% (w/v) PEG 4000, 0.1 M sodium acetate, pH 4.6 (2F2 Fab-210-1); 0.1 M CHES, pH 9.6%, and 20% (w/v) PEG 8000 (2F2 Fab-210-2); 0.2 M potassium acetate and 20% (w/v) PEG 3350 (2F2 Fab-210-3); 0.1 M sodium citrate, pH 5.0, and PEG 6000 (2F2 Fab-210-4); and 0.2 M disodium tartrate and 20% (w/v) PEG 3350 (2F2 Fab-210-5). Crystals appeared after 1–3 days and were cryoprotected in 15% (v/v) ethylene glycol (2F2 Fab-210-1 and 2F2 Fab-210-3), 20% (v/v) ethylene glycol (2F2 Fab-210-2 and 2F2 Fab-210-5) or 25% glycerol (2F2 Fab-210-4), before being flash-frozen in liquid nitrogen.</p><p>Purified 2E10.E9 Fab was concentrated and diluted to 10 mg/mL with peptide 247-4 in a 1:5 molar ratio and immediately used for setting up crystal trays. After complexing with peptides 247-2 or 247-3 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) in a 2:1 molar ratio, 2E10.E9 Fab-peptide complexes were purified by size-exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare), concentrated, and diluted to 10 mg/mL. The 2E10.E9 Fab-peptide complexes were mixed in a 1:1 ratio with the following conditions to obtain crystals: 0.2 M potassium sodium tartrate and 20% (w/v) PEG 3350 (2E10.E9 Fab-247-4); 0.08 M sodium acetate, pH 4.6, 20% glycerol (v/v), and 1.6 M ammonium sulfate (2E10.E9 Fab-247-2); and 0.1 M sodium cacodylate, pH 6.5, 0.2 M sodium acetate, and 30% (w/v) PEG 8000 (2E10.E9 Fab-247-3). Crystals appeared after 1–5 days and were cryoprotected in 20% (v/v) glycerol (2E10.E9 Fab-247-4) or 20% ethylene glycol (2E10.E9 Fab-247-2) before being flash-frozen in liquid nitrogen. For 2E10.E9 Fab-247-3 crystals, no additional cryoprotectant was added.</p><p>Data were collected at the 23-ID-D or 23-ID-B beamlines at the Argonne National Laboratory Advanced Photon Source. All datasets were processed and scaled using XDS (<xref ref-type="bibr" rid="bib36">Kabsch, 2010</xref>). The structures were determined by molecular replacement using Phaser (<xref ref-type="bibr" rid="bib47">McCoy et al., 2007</xref>). Refinement of the structures was performed using phenix.refine (<xref ref-type="bibr" rid="bib2">Adams et al., 2010</xref>) and iterations of refinement using Coot (<xref ref-type="bibr" rid="bib22">Emsley et al., 2010</xref>). Access to all software was supported through SBGrid (<xref ref-type="bibr" rid="bib52">Morin et al., 2013</xref>). Prediction of secondary structure of the co-crystallized peptides was performed with Stride (<xref ref-type="bibr" rid="bib29">Heinig and Frishman, 2004</xref>). Fab-peptide and Fab-Fab contacts were analyzed using the PDBePisa server (<xref ref-type="bibr" rid="bib40">Krissinel and Henrick, 2007</xref>). The detection of intramolecular H-bonds in peptides was performed with PyMOL (<xref ref-type="bibr" rid="bib78">Schrödinger, 2015</xref>).</p></sec><sec id="s4-13"><title>Negative stain EM</title><p>2F2 Fab-PvCSPvk210 or 2E10.E9 Fab-PvCSPvk247 complexes were purified on a Superose 6 Increase 10/300 GL column (GE Healthcare) and diluted to 50 µg/mL. 2F2 Fab-210-6, 2E10.E9 Fab-247-2, 3D11 Fab-NPNDx2, and 1210 Fab-NANP<sub>5</sub> peptide complexes were purified on a Superdex 200 Increase 10/300 GL column (GE Healthcare) and diluted to 25 µg/mL. Samples were deposited onto homemade carbon film coated grids and stained with 2% uranyl formate. Specimens were imaged with a FEI Tecnai T20 electron microscope operating at 200 kV with an Orius charge-coupled device (CCD) camera (Gatan Inc). A calibrated 34,483× magnification, resulting in a pixel size of 2.71 Å, was used for data collection. Particle selection, extraction, and three rounds of 2D classification with 50 classes were performed with Relion (<xref ref-type="bibr" rid="bib77">Scheres, 2012</xref>) and cryoSPARC v2 (<xref ref-type="bibr" rid="bib69">Punjani et al., 2017</xref>).</p></sec><sec id="s4-14"><title>Cryo-EM data collection and image processing</title><p>2F2 Fab-PvCSPvk210 and 2E10.E9 Fab-PvCSPvk247 complexes were purified via Superose 6 Increase 10/300 GL chromatography (GE Healthcare) and concentrated to 0.5 mg/mL. 3 µL of the sample was deposited on homemade holey gold grids (<xref ref-type="bibr" rid="bib46">Marr et al., 2014</xref>), which were glow-discharged in air for 15 s before use. Samples were blotted for 12.0 s and subsequently plunge-frozen in a mixture of liquid ethane and propane (<xref ref-type="bibr" rid="bib83">Tivol et al., 2008</xref>) using a modified FEI Vitrobot (maintained at 4°C and 100% humidity). Data collection was performed with a FEI Tecnai F20 microscope operated at 200 kV with a K2 camera (Gatan Inc). A calibrated 34,483× magnification, resulting in a pixel size of 1.45 Å, and defocus range between 1.5 and 2.8 µm were used for data collection. Exposures were fractionated as movies of 30 frames with a total exposure of 35 electrons/Å<sup>2</sup>. A total of 269 movies were obtained for the 2E10.E9 Fab-PvCSPvk247 complex and 169 movies for the 2F2 Fab-PvCSPvk210 complex. Image processing was carried out in cryoSPARC v2 (<xref ref-type="bibr" rid="bib69">Punjani et al., 2017</xref>). Initial specimen motion correction, exposure weighting, and CTF parameters estimation were done using patch-based algorithms. 100,133 and 87,287 particle images were extracted from micrographs of 2E10.E9 Fab-PvCSPvk247 and 2F2 Fab-PvCSPvk210 complex, respectively, and subjected to 4–5 rounds of 2D classification.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Funding acquisition, Methodology, Validation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Funding acquisition, Methodology, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Summary of CSP-derived peptides used in this study.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-72908-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Intramolecular H-bonds (3.0 A cutoff) in PvCSP peptides observed in Fab-peptide co-crystal structures.</title><p>No intramolecular H-bonds were detected for peptide 247-4.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-72908-supp2-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-72908-transrepform1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>X-ray crystallography structures are accessible from the Protein Data Bank under PDB IDs: 7RLV (2F2 Fab-210-1), 7RLW (2F2 Fab-210-2), 7RLX (2F2 Fab-210-3), 7RLY (2F2 Fab-210-4), 7RLZ (2F2 Fab-210-5), 7RM1 (2E10.E9 Fab-247-2), 7RM3 (2E10.E9 Fab-247-3), 7RM0 (2E10.E9 Fab-247-4).</p><p>The following datasets was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Antibody 2F2 in complex with P. vivax CSP peptide GDRADGQPAGDRADGQPA</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7RLV">7RLV</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Antibody 2F2 in complex with P. vivax CSP peptide GDRAAGQPAGDRAAGQPA</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7RLW">7RLW</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Antibody 2F2 in complex with P. vivax CSP peptide GDRADGQPAGDRAAGQPA</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7RLX">7RLX</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Antibody 2F2 in complex with P. vivax CSP peptide DRAAGQPAGDRADGQPA</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7RLY">7RLY</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Antibody 2F2 in complex with P. vivax CSP peptide GDRAAGQPAGNGAGGQAA</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7RLZ">7RLZ</pub-id></element-citation></p><p><element-citation id="dataset6" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Ivanochko</surname><given-names>D</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Antibody 2E10.E9 in complex with P. vivax CSP peptide ANGAGNQPGANGAGNQPG</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7RM0">7RM0</pub-id></element-citation></p><p><element-citation id="dataset7" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Ivanochko</surname><given-names>D</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Antibody 2F2 in complex with P. vivax CSP peptide EDGAGNQPGANGAGNQPGANGAGNQPG</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7RM1">7RM1</pub-id></element-citation></p><p><element-citation id="dataset8" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Ivanochko</surname><given-names>D</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Antibody 2E10.E9 in complex with P. vivax CSP peptide ANGAGNQPGANGAGNQPGANGAGGQAA</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7RM3">7RM3</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. S Scally for his input during the course of this work. We are grateful to Dr. S Benlekbir for advice regarding specimen preparation. This work was supported by the CIFAR Azrieli Global Scholar program (JPJ), the Ontario Early Researcher Award program (JPJ), the Canada Research Chair program (JLR, JPJ), and the Canadian Institutes of Health Research (RP). IK and DI are supported by SickKids Restracomp Fellowships. This research was enabled in part by support provided by Compute Canada (<ext-link ext-link-type="uri" xlink:href="https://www.computecanada.ca/">https://www.computecanada.ca/</ext-link>). The ITC and BLI instruments were accessed at the Structural and Biophysical Core Facility, The Hospital for Sick Children, supported by the Canada Foundation for Innovation and Ontario Research Fund. X-ray diffraction experiments were performed at GM/CAAPS, which has been funded in whole or in part with federal funds from the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006). The Eiger 16M detector was funded by an NIH–Office of Research Infrastructure Programs High-End Instrumentation grant (1S10OD012289-01A1). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science user facility operated for the DOE Office of Science by Argonne National Laboratory under contract DE-AC02-06CH11357. The following reagents were obtained through BEI Resources, NIAID, NIH: MRA-184, Hybridoma 2F2 Anti-<italic>Plasmodium vivax</italic> Circumsporozoite Protein (CSP) and MRA-185, Hybridoma 2E10.E9 Anti-<italic>Plasmodium vivax</italic> Circumsporozoite Protein (CSP). X-ray crystallography structures are accessible from the Protein Data Bank under PDB IDs: 7RLV (2F2 Fab-210-1), 7RLW (2F2 Fab-210-2), 7RLX (2F2 Fab-210-3), 7RLY (2F2 Fab-210-4), 7RLZ (2F2 Fab-210-5), 7RM1 (2E10.E9 Fab-247-2), 7RM3 (2E10.E9 Fab-247-3), and 7RM0 (2E10.E9 Fab-247-4).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>MJ</given-names></name><name><surname>Murtola</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Páll</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name><name><surname>Hess</surname><given-names>B</given-names></name><name><surname>Lindahl</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers</article-title><source>SoftwareX</source><volume>1–2</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.softx.2015.06.001</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Hung</surname><given-names>LW</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>R</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Zwart</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adepoju</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RTS,S malaria vaccine pilots in three African countries</article-title><source>Lancet</source><volume>393</volume><elocation-id>1685</elocation-id><pub-id pub-id-type="doi">10.1016/S0140-6736(19)30937-7</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandre</surname><given-names>MA</given-names></name><name><surname>Ferreira</surname><given-names>CO</given-names></name><name><surname>Siqueira</surname><given-names>AM</given-names></name><name><surname>Magalhães</surname><given-names>BL</given-names></name><name><surname>Mourão</surname><given-names>MPG</given-names></name><name><surname>Lacerda</surname><given-names>MV</given-names></name><name><surname>Alecrim</surname><given-names>MGC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Severe Plasmodium vivax malaria, Brazilian Amazon</article-title><source>Emerging Infectious Diseases</source><volume>16</volume><fpage>1611</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.3201/eid1610.100685</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnot</surname><given-names>DE</given-names></name><name><surname>Barnwell</surname><given-names>JW</given-names></name><name><surname>Tam</surname><given-names>JP</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name><name><surname>Nussenzweig</surname><given-names>RS</given-names></name><name><surname>Enea</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Circumsporozoite protein of Plasmodium vivax: Gene cloning and characterization of the immunodominant epitope</article-title><source>Science</source><volume>230</volume><fpage>815</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1126/science.2414847</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Balaban</surname><given-names>AE</given-names></name><name><surname>Kanatani</surname><given-names>S</given-names></name><name><surname>Mitra</surname><given-names>J</given-names></name><name><surname>Gregory</surname><given-names>J</given-names></name><name><surname>Vartak</surname><given-names>N</given-names></name><name><surname>Sinnis-Bourozikas</surname><given-names>A</given-names></name><name><surname>Frischknecht</surname><given-names>F</given-names></name><name><surname>Ha</surname><given-names>T</given-names></name><name><surname>Sinnis</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The Repeat Region of the Circumsporozoite Protein Is an Elastic Linear Spring with a Functional Role in Plasmodium Sporozoite Motility</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.05.12.443759</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardají</surname><given-names>A</given-names></name><name><surname>Martínez-Espinosa</surname><given-names>FE</given-names></name><name><surname>Arévalo-Herrera</surname><given-names>M</given-names></name><name><surname>Padilla</surname><given-names>N</given-names></name><name><surname>Kochar</surname><given-names>S</given-names></name><name><surname>Ome-Kaius</surname><given-names>M</given-names></name><name><surname>Bôtto-Menezes</surname><given-names>C</given-names></name><name><surname>Castellanos</surname><given-names>ME</given-names></name><name><surname>Kochar</surname><given-names>DK</given-names></name><name><surname>Kochar</surname><given-names>SK</given-names></name><name><surname>Betuela</surname><given-names>I</given-names></name><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Rogerson</surname><given-names>S</given-names></name><name><surname>Chitnis</surname><given-names>C</given-names></name><name><surname>Hans</surname><given-names>D</given-names></name><name><surname>Menegon</surname><given-names>M</given-names></name><name><surname>Severini</surname><given-names>C</given-names></name><name><surname>Del Portillo</surname><given-names>H</given-names></name><name><surname>Dobaño</surname><given-names>C</given-names></name><name><surname>Mayor</surname><given-names>A</given-names></name><name><surname>Ordi</surname><given-names>J</given-names></name><name><surname>Piqueras</surname><given-names>M</given-names></name><name><surname>Sanz</surname><given-names>S</given-names></name><name><surname>Wahlgren</surname><given-names>M</given-names></name><name><surname>Slutsker</surname><given-names>L</given-names></name><name><surname>Desai</surname><given-names>M</given-names></name><name><surname>Menéndez</surname><given-names>C</given-names></name><collab>PregVax Study Group</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Burden and impact of Plasmodium vivax in pregnancy: A multi-centre prospective observational study</article-title><source>PLOS Neglected Tropical Diseases</source><volume>11</volume><elocation-id>e0005606</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005606</pub-id><pub-id pub-id-type="pmid">28604825</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berendsen</surname><given-names>HJC</given-names></name><name><surname>Postma</surname><given-names>JPM</given-names></name><name><surname>van Gunsteren</surname><given-names>WF</given-names></name><name><surname>DiNola</surname><given-names>A</given-names></name><name><surname>Haak</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Molecular dynamics with coupling to an external bath</article-title><source>The Journal of Chemical Physics</source><volume>81</volume><fpage>3684</fpage><lpage>3690</lpage><pub-id pub-id-type="doi">10.1063/1.448118</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berendsen</surname><given-names>HJC</given-names></name><name><surname>van der Spoel</surname><given-names>D</given-names></name><name><surname>van Drunen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>GROMACS: A message-passing parallel molecular dynamics implementation</article-title><source>Computer Physics Communications</source><volume>91</volume><fpage>43</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/0010-4655(95)00042-E</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>RB</given-names></name><name><surname>Hummer</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides</article-title><source>The Journal of Physical Chemistry. B</source><volume>113</volume><fpage>9004</fpage><lpage>9015</lpage><pub-id pub-id-type="doi">10.1021/jp901540t</pub-id><pub-id pub-id-type="pmid">19514729</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>RB</given-names></name><name><surname>Mittal</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Protein simulations with an optimized water model: cooperative helix formation and temperature-induced unfolded state collapse</article-title><source>The Journal of Physical Chemistry. B</source><volume>114</volume><fpage>14916</fpage><lpage>14923</lpage><pub-id pub-id-type="doi">10.1021/jp108618d</pub-id><pub-id pub-id-type="pmid">21038907</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>DS</given-names></name><name><surname>Avila-Sakar</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Visualizing Proteins and Macromolecular Complexes by Negative Stain EM: from Grid Preparation to Image Acquisition</article-title><source>Journal of Visualized Experiments</source><volume>58</volume><elocation-id>3227</elocation-id><pub-id pub-id-type="doi">10.3791/3227</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussi</surname><given-names>G</given-names></name><name><surname>Donadio</surname><given-names>D</given-names></name><name><surname>Parrinello</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Canonical sampling through velocity rescaling</article-title><source>The Journal of Chemical Physics</source><volume>126</volume><elocation-id>014101</elocation-id><pub-id pub-id-type="doi">10.1063/1.2408420</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera-Mora</surname><given-names>M</given-names></name><name><surname>Fonseca</surname><given-names>JA</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Oliveira-Ferreira</surname><given-names>J</given-names></name><name><surname>Lima-Junior</surname><given-names>JC</given-names></name><name><surname>Calvo-Calle</surname><given-names>JM</given-names></name><name><surname>Moreno</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera</article-title><source>Infection and Immunity</source><volume>83</volume><fpage>3749</fpage><lpage>3761</lpage><pub-id pub-id-type="doi">10.1128/IAI.00480-15</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>C</given-names></name><name><surname>Frevert</surname><given-names>U</given-names></name><name><surname>Sinnis</surname><given-names>P</given-names></name><name><surname>Takacs</surname><given-names>B</given-names></name><name><surname>Clavijo</surname><given-names>P</given-names></name><name><surname>Santos</surname><given-names>MJ</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of <italic>Plasmodium falciparum</italic> sporozoites</article-title><source>Cell</source><volume>70</volume><fpage>1021</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90251-7</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chenet</surname><given-names>SM</given-names></name><name><surname>Tapia</surname><given-names>LL</given-names></name><name><surname>Escalante</surname><given-names>AA</given-names></name><name><surname>Durand</surname><given-names>S</given-names></name><name><surname>Lucas</surname><given-names>C</given-names></name><name><surname>Bacon</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genetic diversity and population structure of genes encoding vaccine candidate antigens of Plasmodium vivax</article-title><source>Malaria Journal</source><volume>11</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-11-68</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>D</given-names></name><name><surname>Sattabongkot</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>CS</given-names></name><name><surname>Kong</surname><given-names>DH</given-names></name><name><surname>Ha</surname><given-names>KS</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Tsuboi</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>ET</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population</article-title><source>Malaria Journal</source><volume>12</volume><elocation-id>323</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-12-323</pub-id><pub-id pub-id-type="pmid">24034268</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppi</surname><given-names>A</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Pradel</surname><given-names>G</given-names></name><name><surname>Bennett</surname><given-names>BL</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Roggero</surname><given-names>MA</given-names></name><name><surname>Corradin</surname><given-names>G</given-names></name><name><surname>Persson</surname><given-names>C</given-names></name><name><surname>Tewari</surname><given-names>R</given-names></name><name><surname>Sinnis</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>341</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1084/jem.20101488</pub-id><pub-id pub-id-type="pmid">21262960</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darden</surname><given-names>T</given-names></name><name><surname>York</surname><given-names>D</given-names></name><name><surname>Pedersen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems</article-title><source>The Journal of Chemical Physics</source><volume>98</volume><fpage>10089</fpage><lpage>10092</lpage><pub-id pub-id-type="doi">10.1063/1.464397</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>SJ</given-names></name><name><surname>Sack</surname><given-names>BK</given-names></name><name><surname>King</surname><given-names>CR</given-names></name><name><surname>Nielsen</surname><given-names>CM</given-names></name><name><surname>Rayner</surname><given-names>JC</given-names></name><name><surname>Higgins</surname><given-names>MK</given-names></name><name><surname>Long</surname><given-names>CA</given-names></name><name><surname>Seder</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Malaria Vaccines: Recent Advances and New Horizons</article-title><source>Cell Host &amp; Microbe</source><volume>24</volume><fpage>43</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.06.008</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyson</surname><given-names>HJ</given-names></name><name><surname>Satterthwait</surname><given-names>AC</given-names></name><name><surname>Lerner</surname><given-names>RA</given-names></name><name><surname>Wright</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Conformational preferences of synthetic peptides derived from the immunodominant site of the circumsporozoite protein of <italic>Plasmodium falciparum</italic> by 1H NMR</article-title><source>Biochemistry</source><volume>29</volume><fpage>7828</fpage><lpage>7837</lpage><pub-id pub-id-type="doi">10.1021/bi00486a008</pub-id><pub-id pub-id-type="pmid">2261440</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of Coot</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essmann</surname><given-names>U</given-names></name><name><surname>Perera</surname><given-names>L</given-names></name><name><surname>Berkowitz</surname><given-names>ML</given-names></name><name><surname>Darden</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Pedersen</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A smooth particle mesh Ewald method</article-title><source>The Journal of Chemical Physics</source><volume>103</volume><fpage>8577</fpage><lpage>8593</lpage><pub-id pub-id-type="doi">10.1063/1.470117</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genton</surname><given-names>B</given-names></name><name><surname>D’Acremont</surname><given-names>V</given-names></name><name><surname>Rare</surname><given-names>L</given-names></name><name><surname>Baea</surname><given-names>K</given-names></name><name><surname>Reeder</surname><given-names>JC</given-names></name><name><surname>Alpers</surname><given-names>MP</given-names></name><name><surname>Müller</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Plasmodium vivax and mixed infections are associated with severe malaria in children: A prospective cohort study from Papua New Guinea</article-title><source>PLOS Medicine</source><volume>5</volume><elocation-id>e127</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0050127</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimenez</surname><given-names>AM</given-names></name><name><surname>Lima</surname><given-names>LC</given-names></name><name><surname>Françoso</surname><given-names>KS</given-names></name><name><surname>Denapoli</surname><given-names>PMA</given-names></name><name><surname>Panatieri</surname><given-names>R</given-names></name><name><surname>Bargieri</surname><given-names>DY</given-names></name><name><surname>Thiberge</surname><given-names>JM</given-names></name><name><surname>Andolina</surname><given-names>C</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Renia</surname><given-names>L</given-names></name><name><surname>Nussenzweig</surname><given-names>RS</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name><name><surname>Amino</surname><given-names>R</given-names></name><name><surname>Rodrigues</surname><given-names>MM</given-names></name><name><surname>Soares</surname><given-names>IS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>1275</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.01275</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>UCSF ChimeraX: Meeting modern challenges in visualization and analysis</article-title><source>Protein Science: A Publication of the Protein Society</source><volume>27</volume><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/pro.3235</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González</surname><given-names>JM</given-names></name><name><surname>Hurtado</surname><given-names>S</given-names></name><name><surname>Arévalo-Herrera</surname><given-names>M</given-names></name><name><surname>Herrera</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Variants of the Plasmodium vivax circumsporozoite protein (VK210 and VK247) in Colombian isolates</article-title><source>Memorias Do Instituto Oswaldo Cruz</source><volume>96</volume><fpage>709</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1590/s0074-02762001000500023</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosline</surname><given-names>J</given-names></name><name><surname>Lillie</surname><given-names>M</given-names></name><name><surname>Carrington</surname><given-names>E</given-names></name><name><surname>Guerette</surname><given-names>P</given-names></name><name><surname>Ortlepp</surname><given-names>C</given-names></name><name><surname>Savage</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Elastic proteins: Biological roles and mechanical properties</article-title><source>Philosophical Transactions of the Royal Society B: Biological Sciences</source><volume>357</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1098/rstb.2001.1022</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinig</surname><given-names>M</given-names></name><name><surname>Frishman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>STRIDE: a web server for secondary structure assignment from known atomic coordinates of proteins</article-title><source>Nucleic Acids Research</source><volume>32</volume><fpage>W500</fpage><lpage>W502</lpage><pub-id pub-id-type="doi">10.1093/nar/gkh429</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation</article-title><source>Journal of Chemical Theory and Computation</source><volume>4</volume><fpage>116</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1021/ct700200b</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>W</given-names></name><name><surname>Dalke</surname><given-names>A</given-names></name><name><surname>Schulten</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>VMD: visual molecular dynamics</article-title><source>Journal of Molecular Graphics</source><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id><pub-id pub-id-type="pmid">8744570</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Matplotlib: A 2D Graphics Environment</article-title><source>Computing in Science &amp; Engineering</source><volume>9</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1109/MCSE.2007.55</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imkeller</surname><given-names>K</given-names></name><name><surname>Scally</surname><given-names>SW</given-names></name><name><surname>Bosch</surname><given-names>A</given-names></name><name><surname>Martí</surname><given-names>GP</given-names></name><name><surname>Costa</surname><given-names>G</given-names></name><name><surname>Triller</surname><given-names>G</given-names></name><name><surname>Murugan</surname><given-names>R</given-names></name><name><surname>Renna</surname><given-names>V</given-names></name><name><surname>Jumaa</surname><given-names>H</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Mordmüller</surname><given-names>B</given-names></name><name><surname>Levashina</surname><given-names>EA</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name><name><surname>Wardemann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope</article-title><source>Science</source><volume>360</volume><fpage>1358</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1126/science.aar5304</pub-id><pub-id pub-id-type="pmid">29880723</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>WL</given-names></name><name><surname>Chandrasekhar</surname><given-names>J</given-names></name><name><surname>Madura</surname><given-names>JD</given-names></name><name><surname>Impey</surname><given-names>RW</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Comparison of simple potential functions for simulating liquid water</article-title><source>The Journal of Chemical Physics</source><volume>79</volume><fpage>926</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1063/1.445869</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julien</surname><given-names>JP</given-names></name><name><surname>Wardemann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Antibodies against <italic>Plasmodium falciparum</italic> malaria at the molecular level</article-title><source>Nature Reviews. Immunology</source><volume>19</volume><fpage>761</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0209-5</pub-id><pub-id pub-id-type="pmid">31462718</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>XDS</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id><pub-id pub-id-type="pmid">20124692</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kain</surname><given-names>KC</given-names></name><name><surname>Brown</surname><given-names>AE</given-names></name><name><surname>Webster</surname><given-names>HK</given-names></name><name><surname>Wirtz</surname><given-names>RA</given-names></name><name><surname>Keystone</surname><given-names>JS</given-names></name><name><surname>Rodriguez</surname><given-names>MH</given-names></name><name><surname>Kinahan</surname><given-names>J</given-names></name><name><surname>Rowland</surname><given-names>M</given-names></name><name><surname>Lanar</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Circumsporozoite genotyping of global isolates of Plasmodium vivax from dried blood specimens</article-title><source>Journal of Clinical Microbiology</source><volume>30</volume><fpage>1863</fpage><lpage>1866</lpage><pub-id pub-id-type="doi">10.1128/jcm.30.7.1863-1866.1992</pub-id><pub-id pub-id-type="pmid">1629344</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TS</given-names></name><name><surname>Kim</surname><given-names>HH</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Na</surname><given-names>BK</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><name><surname>Sohn</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Prevalence of Plasmodium vivax VK210 and VK247 subtype in Myanmar</article-title><source>Malaria Journal</source><volume>9</volume><elocation-id>195</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-9-195</pub-id><pub-id pub-id-type="pmid">20615261</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisalu</surname><given-names>NK</given-names></name><name><surname>Idris</surname><given-names>AH</given-names></name><name><surname>Weidle</surname><given-names>C</given-names></name><name><surname>Flores-Garcia</surname><given-names>Y</given-names></name><name><surname>Flynn</surname><given-names>BJ</given-names></name><name><surname>Sack</surname><given-names>BK</given-names></name><name><surname>Murphy</surname><given-names>S</given-names></name><name><surname>Schön</surname><given-names>A</given-names></name><name><surname>Freire</surname><given-names>E</given-names></name><name><surname>Francica</surname><given-names>JR</given-names></name><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Gregory</surname><given-names>J</given-names></name><name><surname>March</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>H-X</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Wiehe</surname><given-names>K</given-names></name><name><surname>Trama</surname><given-names>AM</given-names></name><name><surname>Saunders</surname><given-names>KO</given-names></name><name><surname>Gladden</surname><given-names>MA</given-names></name><name><surname>Monroe</surname><given-names>A</given-names></name><name><surname>Bonsignori</surname><given-names>M</given-names></name><name><surname>Kanekiyo</surname><given-names>M</given-names></name><name><surname>Wheatley</surname><given-names>AK</given-names></name><name><surname>McDermott</surname><given-names>AB</given-names></name><name><surname>Farney</surname><given-names>SK</given-names></name><name><surname>Chuang</surname><given-names>G-Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Kc</surname><given-names>N</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Sinnis</surname><given-names>P</given-names></name><name><surname>Bhatia</surname><given-names>SN</given-names></name><name><surname>Kappe</surname><given-names>SHI</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Zavala</surname><given-names>F</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Seder</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite</article-title><source>Nature Medicine</source><volume>24</volume><fpage>408</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/nm.4512</pub-id><pub-id pub-id-type="pmid">29554083</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krissinel</surname><given-names>E</given-names></name><name><surname>Henrick</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inference of macromolecular assemblies from crystalline state</article-title><source>Journal of Molecular Biology</source><volume>372</volume><fpage>774</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.05.022</pub-id><pub-id pub-id-type="pmid">17681537</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krotoski</surname><given-names>WA</given-names></name><name><surname>Collins</surname><given-names>WE</given-names></name><name><surname>Bray</surname><given-names>RS</given-names></name><name><surname>Garnham</surname><given-names>PC</given-names></name><name><surname>Cogswell</surname><given-names>FB</given-names></name><name><surname>Gwadz</surname><given-names>RW</given-names></name><name><surname>Killick-Kendrick</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>R</given-names></name><name><surname>Sinden</surname><given-names>R</given-names></name><name><surname>Koontz</surname><given-names>LC</given-names></name><name><surname>Stanfill</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>31</volume><fpage>1291</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1982.31.1291</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Thai</surname><given-names>E</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Rubinstein</surname><given-names>JL</given-names></name><name><surname>Pomès</surname><given-names>R</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural ordering of the Plasmodium berghei circumsporozoite protein repeats by inhibitory antibody 3D11</article-title><source>eLife</source><volume>9</volume><elocation-id>e59018</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.59018</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindorff-Larsen</surname><given-names>K</given-names></name><name><surname>Maragakis</surname><given-names>P</given-names></name><name><surname>Piana</surname><given-names>S</given-names></name><name><surname>Eastwood</surname><given-names>MP</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Systematic Validation of Protein Force Fields against Experimental Data</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e32131</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0032131</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lover</surname><given-names>AA</given-names></name><name><surname>Baird</surname><given-names>JK</given-names></name><name><surname>Gosling</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Malaria Elimination: Time to Target All Species</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>99</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.17-0869</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacKerell</surname><given-names>AD</given-names></name><name><surname>Bashford</surname><given-names>D</given-names></name><name><surname>Bellott</surname><given-names>M</given-names></name><name><surname>Dunbrack</surname><given-names>RL</given-names></name><name><surname>Evanseck</surname><given-names>JD</given-names></name><name><surname>Field</surname><given-names>MJ</given-names></name><name><surname>Fischer</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Ha</surname><given-names>S</given-names></name><name><surname>Joseph-McCarthy</surname><given-names>D</given-names></name><name><surname>Kuchnir</surname><given-names>L</given-names></name><name><surname>Kuczera</surname><given-names>K</given-names></name><name><surname>Lau</surname><given-names>FTK</given-names></name><name><surname>Mattos</surname><given-names>C</given-names></name><name><surname>Michnick</surname><given-names>S</given-names></name><name><surname>Ngo</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>DT</given-names></name><name><surname>Prodhom</surname><given-names>B</given-names></name><name><surname>Karplus</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins</article-title><source>The Journal of Physical Chemistry B</source><volume>102</volume><fpage>3586</fpage><lpage>3616</lpage><pub-id pub-id-type="doi">10.1021/jp973084f</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marr</surname><given-names>CR</given-names></name><name><surname>Benlekbir</surname><given-names>S</given-names></name><name><surname>Rubinstein</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fabrication of carbon films with ∼ 500nm holes for cryo-EM with a direct detector device</article-title><source>Journal of Structural Biology</source><volume>185</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2013.11.002</pub-id><pub-id pub-id-type="pmid">24269484</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Winn</surname><given-names>MD</given-names></name><name><surname>Storoni</surname><given-names>LC</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Phaser crystallographic software</article-title><source>Journal of Applied Crystallography</source><volume>40</volume><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id><pub-id pub-id-type="pmid">19461840</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGibbon</surname><given-names>RT</given-names></name><name><surname>Beauchamp</surname><given-names>KA</given-names></name><name><surname>Harrigan</surname><given-names>MP</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Swails</surname><given-names>JM</given-names></name><name><surname>Hernández</surname><given-names>CX</given-names></name><name><surname>Schwantes</surname><given-names>CR</given-names></name><name><surname>Wang</surname><given-names>LP</given-names></name><name><surname>Lane</surname><given-names>TJ</given-names></name><name><surname>Pande</surname><given-names>VS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MDTraj: A Modern Open Library for the Analysis of Molecular Dynamics Trajectories</article-title><source>Biophysical Journal</source><volume>109</volume><fpage>1528</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2015.08.015</pub-id><pub-id pub-id-type="pmid">26488642</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ménard</surname><given-names>R</given-names></name><name><surname>Sultan</surname><given-names>AA</given-names></name><name><surname>Cortes</surname><given-names>C</given-names></name><name><surname>Altszuler</surname><given-names>R</given-names></name><name><surname>van Dijk</surname><given-names>MR</given-names></name><name><surname>Janse</surname><given-names>CJ</given-names></name><name><surname>Waters</surname><given-names>AP</given-names></name><name><surname>Nussenzweig</surname><given-names>RS</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes</article-title><source>Nature</source><volume>385</volume><fpage>336</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1038/385336a0</pub-id><pub-id pub-id-type="pmid">9002517</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Nussenzweig</surname><given-names>RS</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Antibodies to Plasmodium circumsporozoite protein (CSP) inhibit sporozoite’s cell traversal activity</article-title><source>Journal of Immunological Methods</source><volume>377</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2012.01.009</pub-id><pub-id pub-id-type="pmid">22306356</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Marin-Mogollon</surname><given-names>C</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name><name><surname>Mendes</surname><given-names>AM</given-names></name><name><surname>Laak</surname><given-names>R</given-names></name><name><surname>Sturm</surname><given-names>A</given-names></name><name><surname>Geurten</surname><given-names>FJA</given-names></name><name><surname>Miyazaki</surname><given-names>S</given-names></name><name><surname>Chevalley-Maurel</surname><given-names>S</given-names></name><name><surname>Ramesar</surname><given-names>J</given-names></name><name><surname>Kolli</surname><given-names>SK</given-names></name><name><surname>Kroeze</surname><given-names>H</given-names></name><name><surname>Schuijlenburg</surname><given-names>R</given-names></name><name><surname>Salman</surname><given-names>AM</given-names></name><name><surname>Wilder</surname><given-names>BK</given-names></name><name><surname>Reyes-Sandoval</surname><given-names>A</given-names></name><name><surname>Dechering</surname><given-names>KJ</given-names></name><name><surname>Prudêncio</surname><given-names>M</given-names></name><name><surname>Janse</surname><given-names>CJ</given-names></name><name><surname>Franke-Fayard</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Generation of a genetically modified chimeric <italic>Plasmodium falciparum</italic> parasite expressing plasmodium vivax circumsporozoite protein for malaria vaccine development</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>10</volume><elocation-id>591046</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.591046</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>A</given-names></name><name><surname>Eisenbraun</surname><given-names>B</given-names></name><name><surname>Key</surname><given-names>J</given-names></name><name><surname>Sanschagrin</surname><given-names>PC</given-names></name><name><surname>Timony</surname><given-names>MA</given-names></name><name><surname>Ottaviano</surname><given-names>M</given-names></name><name><surname>Sliz</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Collaboration gets the most out of software</article-title><source>eLife</source><volume>2</volume><elocation-id>e01456</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.01456</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Galinski</surname><given-names>MR</given-names></name><name><surname>Baird</surname><given-names>JK</given-names></name><name><surname>Carlton</surname><given-names>JM</given-names></name><name><surname>Kochar</surname><given-names>DK</given-names></name><name><surname>Alonso</surname><given-names>PL</given-names></name><name><surname>Portillo</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite</article-title><source>The Lancet. Infectious Diseases</source><volume>9</volume><fpage>555</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(09)70177-X</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Shakri</surname><given-names>AR</given-names></name><name><surname>Chitnis</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Development of vaccines for Plasmodium vivax malaria</article-title><source>Vaccine</source><volume>33</volume><fpage>7489</fpage><lpage>7495</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.060</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugan</surname><given-names>R</given-names></name><name><surname>Scally</surname><given-names>SW</given-names></name><name><surname>Costa</surname><given-names>G</given-names></name><name><surname>Mustafa</surname><given-names>G</given-names></name><name><surname>Thai</surname><given-names>E</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name><name><surname>Bosch</surname><given-names>A</given-names></name><name><surname>Prieto</surname><given-names>K</given-names></name><name><surname>Levashina</surname><given-names>EA</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name><name><surname>Wardemann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evolution of protective human antibodies against <italic>Plasmodium falciparum</italic> circumsporozoite protein repeat motifs</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1135</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0881-9</pub-id><pub-id pub-id-type="pmid">32451496</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>G</given-names></name><name><surname>Oostenbrink</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dihedral-based segment identification and classification of biopolymers I: proteins</article-title><source>Journal of Chemical Information and Modeling</source><volume>54</volume><fpage>266</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1021/ci400541d</pub-id><pub-id pub-id-type="pmid">24364820</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nardin</surname><given-names>EH</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name><name><surname>Nussenzweig</surname><given-names>RS</given-names></name><name><surname>Collins</surname><given-names>WE</given-names></name><name><surname>Harinasuta</surname><given-names>KT</given-names></name><name><surname>Tapchaisri</surname><given-names>P</given-names></name><name><surname>Chomcharn</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Circumsporozoite proteins of human malaria parasites <italic>Plasmodium falciparum</italic> and <italic>Plasmodium vivax</italic></article-title><source>The Journal of Experimental Medicine</source><volume>156</volume><fpage>20</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1084/jem.156.1.20</pub-id><pub-id pub-id-type="pmid">7045272</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguitragool</surname><given-names>W</given-names></name><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Kumpitak</surname><given-names>C</given-names></name><name><surname>Saeseu</surname><given-names>T</given-names></name><name><surname>Bantuchai</surname><given-names>S</given-names></name><name><surname>Yorsaeng</surname><given-names>R</given-names></name><name><surname>Yimsamran</surname><given-names>S</given-names></name><name><surname>Maneeboonyang</surname><given-names>W</given-names></name><name><surname>Sa-angchai</surname><given-names>P</given-names></name><name><surname>Chaimungkun</surname><given-names>W</given-names></name><name><surname>Rukmanee</surname><given-names>P</given-names></name><name><surname>Puangsa-art</surname><given-names>S</given-names></name><name><surname>Thanyavanich</surname><given-names>N</given-names></name><name><surname>Koepfli</surname><given-names>C</given-names></name><name><surname>Felger</surname><given-names>I</given-names></name><name><surname>Sattabongkot</surname><given-names>J</given-names></name><name><surname>Singhasivanon</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Very high carriage of gametocytes in asymptomatic low-density <italic>Plasmodium falciparum</italic> and <italic>P. vivax</italic> infections in western Thailand</article-title><source>Parasites &amp; Vectors</source><volume>10</volume><elocation-id>512</elocation-id><pub-id pub-id-type="doi">10.1186/s13071-017-2407-y</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyen</surname><given-names>D</given-names></name><name><surname>Torres</surname><given-names>JL</given-names></name><name><surname>Wille-Reece</surname><given-names>U</given-names></name><name><surname>Ockenhouse</surname><given-names>CF</given-names></name><name><surname>Emerling</surname><given-names>D</given-names></name><name><surname>Glanville</surname><given-names>J</given-names></name><name><surname>Volkmuth</surname><given-names>W</given-names></name><name><surname>Flores-Garcia</surname><given-names>Y</given-names></name><name><surname>Zavala</surname><given-names>F</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>King</surname><given-names>CR</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural basis for antibody recognition of the NANP repeats in <italic>Plasmodium falciparum</italic> circumsporozoite protein</article-title><source>PNAS</source><volume>114</volume><fpage>E10438</fpage><lpage>E10445</lpage><pub-id pub-id-type="doi">10.1073/pnas.1715812114</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyen</surname><given-names>D</given-names></name><name><surname>Torres</surname><given-names>JL</given-names></name><name><surname>Cottrell</surname><given-names>CA</given-names></name><name><surname>Richter King</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cryo-EM structure of <italic>P. falciparum</italic> circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts</article-title><source>Science Advances</source><volume>4</volume><elocation-id>eaau8529</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aau8529</pub-id><pub-id pub-id-type="pmid">30324137</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyen</surname><given-names>D</given-names></name><name><surname>Torres</surname><given-names>JL</given-names></name><name><surname>Aoto</surname><given-names>PC</given-names></name><name><surname>Flores-Garcia</surname><given-names>Y</given-names></name><name><surname>Binter</surname><given-names>Š</given-names></name><name><surname>Pholcharee</surname><given-names>T</given-names></name><name><surname>Carroll</surname><given-names>S</given-names></name><name><surname>Reponen</surname><given-names>S</given-names></name><name><surname>Wash</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>Q</given-names></name><name><surname>Lemiale</surname><given-names>F</given-names></name><name><surname>Locke</surname><given-names>E</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>CR</given-names></name><name><surname>Emerling</surname><given-names>D</given-names></name><name><surname>Kellam</surname><given-names>P</given-names></name><name><surname>Zavala</surname><given-names>F</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure and mechanism of monoclonal antibody binding to the junctional epitope of <italic>Plasmodium falciparum</italic> circumsporozoite protein</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008373</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008373</pub-id><pub-id pub-id-type="pmid">32150583</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrinello</surname><given-names>M</given-names></name><name><surname>Rahman</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Polymorphic transitions in single crystals: A new molecular dynamics method</article-title><source>Journal of Applied Physics</source><volume>52</volume><fpage>7182</fpage><lpage>7190</lpage><pub-id pub-id-type="doi">10.1063/1.328693</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrini</surname><given-names>C</given-names></name><name><surname>Taddei</surname><given-names>N</given-names></name><name><surname>Ramazzotti</surname><given-names>M</given-names></name><name><surname>Degl’Innocenti</surname><given-names>D</given-names></name><name><surname>Ramponi</surname><given-names>G</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Chiti</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Glycine residues appear to be evolutionarily conserved for their ability to inhibit aggregation</article-title><source>Structure</source><volume>13</volume><fpage>1143</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1016/j.str.2005.04.022</pub-id><pub-id pub-id-type="pmid">16084386</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pholcharee</surname><given-names>T</given-names></name><name><surname>Oyen</surname><given-names>D</given-names></name><name><surname>Torres</surname><given-names>JL</given-names></name><name><surname>Flores-Garcia</surname><given-names>Y</given-names></name><name><surname>Martin</surname><given-names>GM</given-names></name><name><surname>González-Páez</surname><given-names>GE</given-names></name><name><surname>Emerling</surname><given-names>D</given-names></name><name><surname>Volkmuth</surname><given-names>W</given-names></name><name><surname>Locke</surname><given-names>E</given-names></name><name><surname>King</surname><given-names>CR</given-names></name><name><surname>Zavala</surname><given-names>F</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Diverse Antibody Responses to Conserved Structural Motifs in <italic>Plasmodium falciparum</italic> Circumsporozoite Protein</article-title><source>Journal of Molecular Biology</source><volume>432</volume><fpage>1048</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.12.029</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pholcharee</surname><given-names>T</given-names></name><name><surname>Oyen</surname><given-names>D</given-names></name><name><surname>Flores-Garcia</surname><given-names>Y</given-names></name><name><surname>Gonzalez-Paez</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Williams</surname><given-names>KL</given-names></name><name><surname>Volkmuth</surname><given-names>W</given-names></name><name><surname>Emerling</surname><given-names>D</given-names></name><name><surname>Locke</surname><given-names>E</given-names></name><name><surname>Richter King</surname><given-names>C</given-names></name><name><surname>Zavala</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against <italic>P. falciparum</italic></article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1063</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21221-4</pub-id><pub-id pub-id-type="pmid">33594061</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piana</surname><given-names>S</given-names></name><name><surname>Lindorff-Larsen</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>How Robust Are Protein Folding Simulations with Respect to Force Field Parameterization?</article-title><source>Biophysical Journal</source><volume>100</volume><fpage>L47</fpage><lpage>L49</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2011.03.051</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potocnjak</surname><given-names>P</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Nussenzweig</surname><given-names>RS</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection</article-title><source>The Journal of Experimental Medicine</source><volume>151</volume><fpage>1504</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1084/jem.151.6.1504</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname><given-names>A</given-names></name><name><surname>Rubinstein</surname><given-names>JL</given-names></name><name><surname>Fleet</surname><given-names>DJ</given-names></name><name><surname>Brubaker</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination</article-title><source>Nature Methods</source><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauscher</surname><given-names>S</given-names></name><name><surname>Baud</surname><given-names>S</given-names></name><name><surname>Miao</surname><given-names>M</given-names></name><name><surname>Keeley</surname><given-names>FW</given-names></name><name><surname>Pomès</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Proline and Glycine Control Protein Self-Organization into Elastomeric or Amyloid Fibrils</article-title><source>Structure</source><volume>14</volume><fpage>1667</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1016/j.str.2006.09.008</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichheld</surname><given-names>SE</given-names></name><name><surname>Muiznieks</surname><given-names>LD</given-names></name><name><surname>Huynh</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Ing</surname><given-names>C</given-names></name><name><surname>Miao</surname><given-names>M</given-names></name><name><surname>Sitarz</surname><given-names>EE</given-names></name><name><surname>Pomès</surname><given-names>R</given-names></name><name><surname>Sharpe</surname><given-names>S</given-names></name><name><surname>Keeley</surname><given-names>FW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The evolutionary background and functional consequences of the rs2071307 polymorphism in human tropoelastin</article-title><source>Biopolymers</source><volume>112</volume><elocation-id>e23414</elocation-id><pub-id pub-id-type="doi">10.1002/bip.23414</pub-id><pub-id pub-id-type="pmid">33351193</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rich</surname><given-names>SM</given-names></name><name><surname>Ferreira</surname><given-names>MU</given-names></name><name><surname>Ayala</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The origin of antigenic diversity in <italic>Plasmodium falciparum</italic></article-title><source>Parasitology Today</source><volume>16</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/s0169-4758(00)01741-5</pub-id><pub-id pub-id-type="pmid">10951599</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>R</given-names></name><name><surname>Wirtz</surname><given-names>RA</given-names></name><name><surname>Lanar</surname><given-names>DE</given-names></name><name><surname>Sattabongkot</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>T</given-names></name><name><surname>Waters</surname><given-names>AP</given-names></name><name><surname>Prasittisuk</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Circumsporozoite protein heterogeneity in the human malaria parasite <italic>Plasmodium vivax</italic></article-title><source>Science</source><volume>245</volume><fpage>973</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1126/science.2672336</pub-id><pub-id pub-id-type="pmid">2672336</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Maher</surname><given-names>SP</given-names></name><name><surname>Conway</surname><given-names>AJ</given-names></name><name><surname>Ubalee</surname><given-names>R</given-names></name><name><surname>Chaumeau</surname><given-names>V</given-names></name><name><surname>Andolina</surname><given-names>C</given-names></name><name><surname>Kaba</surname><given-names>SA</given-names></name><name><surname>Vantaux</surname><given-names>A</given-names></name><name><surname>Bakowski</surname><given-names>MA</given-names></name><name><surname>Thomson-Luque</surname><given-names>R</given-names></name><name><surname>Adapa</surname><given-names>SR</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Barnes</surname><given-names>SJ</given-names></name><name><surname>Cooper</surname><given-names>CA</given-names></name><name><surname>Rouillier</surname><given-names>M</given-names></name><name><surname>McNamara</surname><given-names>CW</given-names></name><name><surname>Mikolajczak</surname><given-names>SA</given-names></name><name><surname>Sather</surname><given-names>N</given-names></name><name><surname>Witkowski</surname><given-names>B</given-names></name><name><surname>Campo</surname><given-names>B</given-names></name><name><surname>Kappe</surname><given-names>SHI</given-names></name><name><surname>Lanar</surname><given-names>DE</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Davidson</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>RHY</given-names></name><name><surname>Kyle</surname><given-names>DE</given-names></name><name><surname>Adams</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Author Correction: A comprehensive model for assessment of liver stage therapies targeting <italic>Plasmodium vivax</italic> and <italic>Plasmodium falciparum</italic></article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2317</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04817-1</pub-id><pub-id pub-id-type="pmid">29884783</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scally</surname><given-names>SW</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Peek-Peak-Pique: Repeating Motifs of Subtle Variance Are Targets for Potent Malaria Antibodies</article-title><source>Immunity</source><volume>48</volume><fpage>851</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.04.037</pub-id><pub-id pub-id-type="pmid">29768173</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scally</surname><given-names>SW</given-names></name><name><surname>Murugan</surname><given-names>R</given-names></name><name><surname>Bosch</surname><given-names>A</given-names></name><name><surname>Triller</surname><given-names>G</given-names></name><name><surname>Costa</surname><given-names>G</given-names></name><name><surname>Mordmüller</surname><given-names>B</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Levashina</surname><given-names>EA</given-names></name><name><surname>Wardemann</surname><given-names>H</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1084/jem.20170869</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheres</surname><given-names>SHW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>RELION: Implementation of a Bayesian approach to cryo-EM structure determination</article-title><source>Journal of Structural Biology</source><volume>180</volume><fpage>519</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2012.09.006</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Schrödinger</collab></person-group><year iso-8601-date="2015">2015</year><data-title>The PyMOL Molecular Graphics System</data-title><version designator="PyMOL">PyMOL</version><publisher-name>Schrodinger LLC</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.schrodinger.com/products/pymol">https://www.schrodinger.com/products/pymol</ext-link></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares</surname><given-names>IF</given-names></name><name><surname>López-Camacho</surname><given-names>C</given-names></name><name><surname>Rodrigues-da-Silva</surname><given-names>RN</given-names></name><name><surname>Silva Matos</surname><given-names>A</given-names></name><name><surname>Oliveira Baptista</surname><given-names>B</given-names></name><name><surname>Totino</surname><given-names>PRR</given-names></name><name><surname>Souza</surname><given-names>RM</given-names></name><name><surname>Harrison</surname><given-names>K</given-names></name><name><surname>Gimenez</surname><given-names>AM</given-names></name><name><surname>Freitas</surname><given-names>EO</given-names></name><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Oliveira-Ferreira</surname><given-names>J</given-names></name><name><surname>Daniel-Ribeiro</surname><given-names>CT</given-names></name><name><surname>Reyes-Sandoval</surname><given-names>A</given-names></name><name><surname>Pratt-Riccio</surname><given-names>LR</given-names></name><name><surname>Lima-Junior</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Recombinant Plasmodium vivax circumsporozoite surface protein allelic variants: Antibody recognition by individuals from three communities in the Brazilian Amazon</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>14020</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-70893-3</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahar</surname><given-names>R</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Basco</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Heterogeneity in the circumsporozoite protein gene of Plasmodium malariae isolates from sub-Saharan Africa</article-title><source>Molecular and Biochemical Parasitology</source><volume>92</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/s0166-6851(97)00226-0</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Sack</surname><given-names>BK</given-names></name><name><surname>Oyen</surname><given-names>D</given-names></name><name><surname>Zenklusen</surname><given-names>I</given-names></name><name><surname>Piccoli</surname><given-names>L</given-names></name><name><surname>Barbieri</surname><given-names>S</given-names></name><name><surname>Foglierini</surname><given-names>M</given-names></name><name><surname>Fregni</surname><given-names>CS</given-names></name><name><surname>Marcandalli</surname><given-names>J</given-names></name><name><surname>Jongo</surname><given-names>S</given-names></name><name><surname>Abdulla</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>L</given-names></name><name><surname>Corradin</surname><given-names>G</given-names></name><name><surname>Varani</surname><given-names>L</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Kappe</surname><given-names>SHI</given-names></name><name><surname>Daubenberger</surname><given-names>C</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein</article-title><source>Nature Medicine</source><volume>24</volume><fpage>401</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1038/nm.4513</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>LH</given-names></name><name><surname>Tararam</surname><given-names>CA</given-names></name><name><surname>Lasaro</surname><given-names>MO</given-names></name><name><surname>Camacho</surname><given-names>AGA</given-names></name><name><surname>Ersching</surname><given-names>J</given-names></name><name><surname>Leal</surname><given-names>MT</given-names></name><name><surname>Herrera</surname><given-names>S</given-names></name><name><surname>Bruna-Romero</surname><given-names>O</given-names></name><name><surname>Soares</surname><given-names>IS</given-names></name><name><surname>Nussenzweig</surname><given-names>RS</given-names></name><name><surname>Ertl</surname><given-names>HCJ</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name><name><surname>Rodrigues</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents</article-title><source>Infection and Immunity</source><volume>82</volume><fpage>793</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1128/IAI.01410-13</pub-id><pub-id pub-id-type="pmid">24478093</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tivol</surname><given-names>WF</given-names></name><name><surname>Briegel</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>An improved cryogen for plunge freezing</article-title><source>Microscopy and Microanalysis</source><volume>14</volume><fpage>375</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1017/S1431927608080781</pub-id><pub-id pub-id-type="pmid">18793481</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triller</surname><given-names>G</given-names></name><name><surname>Scally</surname><given-names>SW</given-names></name><name><surname>Costa</surname><given-names>G</given-names></name><name><surname>Pissarev</surname><given-names>M</given-names></name><name><surname>Kreschel</surname><given-names>C</given-names></name><name><surname>Bosch</surname><given-names>A</given-names></name><name><surname>Marois</surname><given-names>E</given-names></name><name><surname>Sack</surname><given-names>BK</given-names></name><name><surname>Murugan</surname><given-names>R</given-names></name><name><surname>Salman</surname><given-names>AM</given-names></name><name><surname>Janse</surname><given-names>CJ</given-names></name><name><surname>Khan</surname><given-names>SM</given-names></name><name><surname>Kappe</surname><given-names>SHI</given-names></name><name><surname>Adegnika</surname><given-names>AA</given-names></name><name><surname>Mordmüller</surname><given-names>B</given-names></name><name><surname>Levashina</surname><given-names>EA</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name><name><surname>Wardemann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies</article-title><source>Immunity</source><volume>47</volume><fpage>1197</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.11.007</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LT</given-names></name><name><surname>Pereira</surname><given-names>LS</given-names></name><name><surname>Flores-Garcia</surname><given-names>Y</given-names></name><name><surname>O’Connor</surname><given-names>J</given-names></name><name><surname>Flynn</surname><given-names>BJ</given-names></name><name><surname>Schön</surname><given-names>A</given-names></name><name><surname>Hurlburt</surname><given-names>NK</given-names></name><name><surname>Dillon</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>ASP</given-names></name><name><surname>Fabra-García</surname><given-names>A</given-names></name><name><surname>Idris</surname><given-names>AH</given-names></name><name><surname>Mayer</surname><given-names>BT</given-names></name><name><surname>Gerber</surname><given-names>MW</given-names></name><name><surname>Gottardo</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>RD</given-names></name><name><surname>Cavett</surname><given-names>N</given-names></name><name><surname>Ballard</surname><given-names>RB</given-names></name><name><surname>Kisalu</surname><given-names>NK</given-names></name><name><surname>Molina-Cruz</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>J</given-names></name><name><surname>Vistein</surname><given-names>R</given-names></name><name><surname>Barillas-Mury</surname><given-names>C</given-names></name><name><surname>Amino</surname><given-names>R</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>King</surname><given-names>NP</given-names></name><name><surname>Sauerwein</surname><given-names>RW</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Cockburn</surname><given-names>IA</given-names></name><name><surname>Zavala</surname><given-names>F</given-names></name><name><surname>Francica</surname><given-names>JR</given-names></name><name><surname>Seder</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver</article-title><source>Immunity</source><volume>53</volume><fpage>733</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.08.014</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>AD</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Kheterpal</surname><given-names>I</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>KD</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wetzel</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis</article-title><source>Journal of Molecular Biology</source><volume>335</volume><fpage>833</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2003.11.008</pub-id><pub-id pub-id-type="pmid">14687578</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="report"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2020">2020</year><source>World Malaria Report 2020</source><publisher-name>World Trade Organization</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.wto.org/">https://www.wto.org/</ext-link></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadava</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>CE</given-names></name><name><surname>Sullivan</surname><given-names>JS</given-names></name><name><surname>Nace</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>T</given-names></name><name><surname>Collins</surname><given-names>WE</given-names></name><name><surname>Ockenhouse</surname><given-names>CF</given-names></name><name><surname>Barnwell</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region</article-title><source>PLOS Neglected Tropical Diseases</source><volume>8</volume><elocation-id>e3268</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003268</pub-id><pub-id pub-id-type="pmid">25329054</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Nussenzweig</surname><given-names>RS</given-names></name><name><surname>Potocnjak</surname><given-names>P</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite</article-title><source>Science</source><volume>207</volume><fpage>71</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1126/science.6985745</pub-id><pub-id pub-id-type="pmid">6985745</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavala</surname><given-names>F</given-names></name><name><surname>Cochrane</surname><given-names>AH</given-names></name><name><surname>Nardin</surname><given-names>EH</given-names></name><name><surname>Nussenzweig</surname><given-names>RS</given-names></name><name><surname>Nussenzweig</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes</article-title><source>The Journal of Experimental Medicine</source><volume>157</volume><fpage>1947</fpage><lpage>1957</lpage><pub-id pub-id-type="doi">10.1084/jem.157.6.1947</pub-id><pub-id pub-id-type="pmid">6189951</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72908.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Frank</surname><given-names>Aaron</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This paper combines simulations and experimental biophysical approaches to probe the molecular basis of antibody recognition of key repeat peptides found on the surface of <italic>Plasmodium vivax</italic>, a parasite that causes malaria. Currently, we know surprisingly little about the mechanism by which antibodies recognize these peptides. Thus, this work provides crucial molecular insights into a recognition process of considerable biomedical significance, which might ultimately inform rational design of novel and more effective antimalarial vaccines.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72908.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Frank</surname><given-names>Aaron</given-names></name><role>Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Tolia</surname><given-names>Niraj H</given-names></name><role>Reviewer</role><aff><institution>National Institute of Allergy and Infectious Diseases</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Structural basis of <italic>Plasmodium vivax</italic> inhibition by antibodies binding to the circumsporozoite protein repeats&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by José Faraldo-Gómez as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Niraj H Tolia (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Overall, the reviewers agree that this paper is strong. The science is rigorous and well described in the manuscript. One area that needs addressing is a more thorough discussion of the biological insights derived from these studies, which, as you know, is a critical component of articles published in <italic>eLife</italic>.</p><p>Additionally, the reviewers have made note of a number of specific issues that must be addressed in your revised submission (see below):<italic>Reviewer #1:</italic></p><p>Plasmodium vivax (Pv), which causes Malaria, is decorated with surface receptors that contain central repeat proteins that antibodies can target to prevent Pv infection. Thus understanding the molecular basis of antibody recognition of the peptides in these repeats regions might help advance our basic science understanding and potentially aid in vaccine design. Here, Kucharska et al., used a battery of techniques to characterize the biophysical properties of two strains of Pv repeat peptides, VK210 and VK247, found in the central repeat regions of the Pv receptor protein, Circumsporozoite protein (CSP). A particular strength of this work is the diversity of biophysical techniques used to study the peptides in the absence and presence of inhibitory antibodies, which enabled the authors to provide a comprehensive picture of the biophysical properties of these peptides. However, lacking from the current account is an articulation of the biological insights derived from these studies.</p><p>1. In Figure 2a, the authors indexed the 210 peptides using letters (a-d), whereas, in other parts of the manuscript, they indexed the peptides using numbers (1-5). The authors should use consistent indexing.</p><p>2. Can the authors clarify the difference between peptides 210-1 and 210-2? In Figure 1, they appear to have the same sequence. Maybe a typo?</p><p>3. The authors report in Figure 1 CD results for the five 210 peptides. However, in Figure 2, they only show MD simulations for four of the 210 peptides. Can the authors comment on why?</p><p>4. The authors should comment on how the elastic moduli they compute compare with other peptides/proteins. For example, do the values fall within the range of what others have calculated for peptides with known elastic properties? This is important because when discussing the molecular basis of 2F2, the authors describe the peptides as elastic, as if self-evident. Are there any easy experiments that the authors can perform to test the MD prediction that these peptides are elastic?</p><p>5. The authors state that &quot;2F2 Fab binds to all tested peptides containing two repeats with similar affinity, with a slight preference for peptide 210-1 (GDRADGQPAGDRADGQPA; 17.0 nM) 137 over 210-2 (GDRAAGQPAGDRAAGQPA; 37.5 nM) (Figure 3A). &quot;</p><p>However, based on Figure 3a, it seems like the slight preference is force 210-3, not 210-1. Am I mistaken?</p><p>6. I know that Figure 3e is already a bit crowded, but the authors should consider annotating the image with the distances associated with the contacts they highlighted (dashed lines).</p><p><italic>Reviewer #2:</italic></p><p>The manuscript from Kucharska et al., investigates the structural basis for antibody recognition of the central repeat regions of the Plasmodium vivax (Pv) circumsporozoite protein (CSP). Similar studies by this group and others have been performed for the <italic>Plasmodium falciparum</italic> (Pf) CSP, but information on Pv has been lacking. Circular dichroism and MD studies indicate that the PvCSP central repeats are largely unstructured. ITC, BLI, X-ray crystallography and EM studies define the structural basis for the recognition of PvCSP repeats from strains VK210 and VK247 by two murine antibodies, 2F2 and 2E10.E9. In the crystal structure of 2E10.E9 in complex with a longer repeat peptide, homotypic 2E10.E9 Fab-Fab interactions are observed, as observed previously for potent antibodies against PfCSP. The EM studies demonstrate that binding of 2F2 or 2E10.E9 Fabs to PvCSP does not induce the central repeat region to form a spiral assembly, as observed for some of the potent PfCSP antibodies against.</p><p>The manuscript is clear, concise, and well written. Although I can not assess the molecular dynamics studies, the structural and biophysical experiments were rigorously performed, with excellent statistics for the 8 crystal structures. This manuscript should be of interest to those investigators involved in malaria vaccine development.<italic>Reviewer #3:</italic></p><p>CSP is a prominent vaccine antigen that has been extensively characterized for <italic>P. falciparum</italic> malaria, but less is known about the <italic>P. vivax</italic> CSP and its potential for antibody-mediated protection. The authors propose that the CSP repeat regions are elastic and may provide a high degree of conformational flexibility relevant for CSP function. They further describe structural studies of the repeat region of <italic>P. vivax</italic> CSP in conjunction with rodent antibodies and show that antibodies that bind the CSP repeat regions appear to tolerate sequence variation observed in the CSP repeats to bind multiple sequences. Multiple antibodies bind a single repeat with interactions observed between the antibodies as well as between antibodies and CSP, consistent with findings from studies of CSP from <italic>P. falciparum</italic> and P. berghei.</p><p>Strengths:</p><p>Comprehensive and high-quality studies that examine the conformational states of CSP repeats alongside biophysical measurements to interrogate the interaction of antibodies with CSP repeats and structural studies to define the interactions.</p><p>The diverse approaches all align to provide a consistent narrative: the CSP repeats of <italic>P. vivax</italic> are inherently flexible, and antibodies can bind these flexible sequences by leveraging homotypic interactions and tolerating sequence variation within repeats.</p><p>CSP is a prominent antigen for the development of vaccines for malaria, and this work may inform further development of <italic>P. vivax</italic> specific vaccines.</p><p>Weaknesses:</p><p>While no studies have been reported to date on <italic>P. vivax</italic> CSP, the findings are somewhat confirmative of publications from the same group on <italic>P. falciparum</italic> and P. berghei CSP.</p><p>The manuscript contains a lot of detailed information that is not easy to follow without a clear simple figure to aid understanding. More proofreading is recommended to minimize errors, improve the content, and increase the clarity of the paper. Specific comments are below (not exhaustive):</p><p>1. Line 64. “nonapeptides … or ….” Should be “nonapeptides … and ….”</p><p>2. A lot of acronyms were used without being clearly defined. Such as Line 66 “4-aa” ; Line 96 “MD simulation” “KC” “HC” “KCDR” etc.</p><p>3. Line 161. Figure 3E referenced in this paragraph did not seem to correlate with Figure 3E. None of the residues mentioned were mentioned in the figure.</p><p>4. Line 171. No Figure 2E is found.</p><p>5. Lack of consistency. Line 66 “motifs of Pf and P.berghei CSP …”</p><p>6. Please use a consistent number format for all Kd values. Such as 1-decimal place is used in Figure 3A and 2- and 3- decimal places were used in Figure 4A.</p><p>7. Line 201. Figure 3E should be Figure 4E.</p><p>8. Line 618. “HC residues are shown in green and KC residues are shown in grey” better written as “HC is shown in green and KC is shown in grey”.</p><p>9. Line 63. “HC residues are shown in blue and KC residues are shown in grey” better written as “HC is shown in green and KC is shown in grey”.</p><p>10. Figure 5C figure legend. The definition of “Green highlight” and “Yellow highlight” seems swapped. Please check accuracy.</p><p>11. Line 303. Please use “proline” and “glycine” instead of P and G.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72908.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Overall, the reviewers agree that this paper is strong. The science is rigorous and well described in the manuscript. One area that needs addressing is a more thorough discussion of the biological insights derived from these studies, which, as you know, is a critical component of articles published in eLife.</p></disp-quote><p>We thank the Editor and Reviewers for their positive assessment of our work and comments in the Reviews. To expand on the biological insights derived from these studies, we have added the following sentences to three paragraphs in (the Discussion):</p><p>“PvCSP peptides have glycine and proline contents of ~22-33% and ~7-11%, respectively, and thus are predicted to fall within the transition region separating amyloidogenic from elastomeric proteins, the latter of which include elastin domains and insect resilin (Rauscher et al., 2006). Moreover, the elastic modulus of PvCSP peptides [~3-5 cal/(mol Å2)] is commensurate with the elastic modulus of peptides modeled after human elastin [~9 cal/(mol Å2)], which requires extensibility and elasticity for its physiological function (Reichheld et al., 2021). This analogy supports the observation that CSP is inherently elastic and suggests that achieving a high degree of conformational disorder may be an essential aspect of CSP function on the surface of sporozoites.”</p><p>“Our data indicate that both mAbs 2F2 and 2E10.E9 are cross-reactive as they bind to different repeat motifs of their respective PvCSP variants with similar affinity and in identical conformations. mAbs 2F2 and 2E10.E9 are, however, not cross-reactive to different strains of Pv (Nardin et al., 1982), due to the significantly different CSP sequences of strains PvCSPvk210 and PvCSPvk247. Although both mAbs 2F2 and 2E10.E9 are inhibitory, only mAb 2F2 was reported to induce aberrations in size and in DNA content of sporozoites, indicating a distinct mechanism of attenuation (Roth et al., 2018), possibly due to the higher affinity to PvCSP and slower dissociation rate of mAb 2F2 compared to mAb 2E10.E9.”</p><p>“Both mAbs 2F2 and 2E10.E9 recognize their respective epitopes using germline-encoded and somatically hypermutated residues. The difference in affinities between mAbs 2E10.E9 and 2F2 and their respective antigen might partially stem from the low lumber of somatic hypermutations of mAb 2E10.E9 (1 in HC, 6 in KC) compared to 2F2 (14 in HC, 4 in KC). Specifically, mAbs 2F2 and 2E10.E9 use nine and six germline-encoded aromatic residues, respectively to mediate contacts with their core epitopes. Germline-encoded mAb 2E10.E9 residue H.Trp50 forms extensive van der Waals interactions with N6 and P8 residues, analogous to IGHV3-33 germline-encoded H.Trp52 in several human mAbs, including mAbs MGG4 (Tan et al., 2018), 1210 (Imkeller et al., 2018), 311 (Oyen et al., 2017), and other antibodies induced by sporozoite immunization (Murugan et al., 2020) or RTS,S vaccination (Pholcharee et al., 2021) (Figure 3—figure supplement 2 D-E). As both human and murine mAbs appear to depend on germline-encoded aromatic residues for CSP recognition, it is likely that CSP repeats prime the mammalian immune system to select antibodies from germline genes with already optimally-positioned aromatic residues.”</p><disp-quote content-type="editor-comment"><p>Additionally, the reviewers have made note of a number of specific issues that must be addressed in your revised submission (see below):</p><p>Reviewer #1:</p><p>Plasmodium vivax (Pv), which causes Malaria, is decorated with surface receptors that contain central repeat proteins that antibodies can target to prevent Pv infection. Thus understanding the molecular basis of antibody recognition of the peptides in these repeats regions might help advance our basic science understanding and potentially aid in vaccine design. Here, Kucharska et al., used a battery of techniques to characterize the biophysical properties of two strains of Pv repeat peptides, VK210 and VK247, found in the central repeat regions of the Pv receptor protein, Circumsporozoite protein (CSP). A particular strength of this work is the diversity of biophysical techniques used to study the peptides in the absence and presence of inhibitory antibodies, which enabled the authors to provide a comprehensive picture of the biophysical properties of these peptides. However, lacking from the current account is an articulation of the biological insights derived from these studies.</p><p>1. In Figure 2a, the authors indexed the 210 peptides using letters (a-d), whereas, in other parts of the manuscript, they indexed the peptides using numbers (1-5). The authors should use consistent indexing.</p></disp-quote><p>To avoid any confusion, we have revised the peptide indexing, which now includes only numbers.</p><disp-quote content-type="editor-comment"><p>2. Can the authors clarify the difference between peptides 210-1 and 210-2? In Figure 1, they appear to have the same sequence. Maybe a typo?</p></disp-quote><p>We thank the reviewer for noticing this typo, the figure has now been corrected accordingly.</p><disp-quote content-type="editor-comment"><p>3. The authors report in Figure 1 CD results for the five 210 peptides. However, in Figure 2, they only show MD simulations for four of the 210 peptides. Can the authors comment on why?</p></disp-quote><p>To probe for any potential longer-range effects on secondary structure propensities, we performed MD simulations <italic>in silico</italic> on four longer 210 peptides (27-aa) compared to five shorter (18-aa) peptides studied experimentally by CD.</p><disp-quote content-type="editor-comment"><p>4. The authors should comment on how the elastic moduli they compute compare with other peptides/proteins. For example, do the values fall within the range of what others have calculated for peptides with known elastic properties? This is important because when discussing the molecular basis of 2F2, the authors describe the peptides as elastic, as if self-evident. Are there any easy experiments that the authors can perform to test the MD prediction that these peptides are elastic?</p></disp-quote><p>We thank the Reviewer for this excellent suggestion. As such, we have added the following sentence to the Discussion:</p><p>“PvCSP peptides have glycine and proline contents of ~22-33% and ~7-11%, respectively, and thus are predicted to fall within the transition region separating amyloidogenic from elastomeric proteins, the latter of which include elastin domains and insect resilin (Rauscher et al., 2006). Moreover, the elastic modulus of PvCSP peptides [~3-5 cal/(mol Å2)] is commensurate with the elastic modulus of peptides modeled after human elastin [~9 cal/(mol Å2)], which requires extensibility and elasticity for its physiological function (Reichheld et al., 2021).”</p><disp-quote content-type="editor-comment"><p>5. The authors state that &quot;2F2 Fab binds to all tested peptides containing two repeats with similar affinity, with a slight preference for peptide 210-1 (GDRADGQPAGDRADGQPA; 17.0 nM) 137 over 210-2 (GDRAAGQPAGDRAAGQPA; 37.5 nM) (Figure 3A). &quot;</p><p>However, based on Figure 3a, it seems like the slight preference is force 210-3, not 210-1. Am I mistaken?</p></disp-quote><p>We thank the Reviewer for this comment, and have revised the corresponding description to accurately reflect the data presented: “2F2 Fab binds to all tested peptides containing two repeats with similar affinity, with a slight preference for peptide 210-3 (GDRADGQPAGDRAAGQPA; 13.8 nM) over 210-2 (GDRAAGQPAGDRAAGQPA; 37.5 nM) (Figure 3A), with other peptides displaying intermediate affinities (17.1-19.1 nM). Peptides 210-3 and 210-2 differ in the 5th residue of the first repeat, which is an aspartic acid for peptide 210-3 and an alanine for peptide 210-2 (GDRA(D/A)GQPA).”</p><disp-quote content-type="editor-comment"><p>6. I know that Figure 3e is already a bit crowded, but the authors should consider annotating the image with the distances associated with the contacts they highlighted (dashed lines).</p></disp-quote><p>As suggested by the Reviewer, we added additional labels to Figure 3E (A9, G10, K.Gly91, K.Phe96,…) in order to highlight the interactions discussed in the text.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>[…]</p><p>The manuscript contains a lot of detailed information that is not easy to follow without a clear simple figure to aid understanding. More proofreading is recommended to minimize errors, improve the content, and increase the clarity of the paper. Specific comments are below (not exhaustive):</p></disp-quote><p>We thank the reviewer for their suggestions. Accordingly, we have proofread the manuscript extensively; specific recommendations have been addressed as follows:</p><disp-quote content-type="editor-comment"><p>1. Line 64. &quot;nonapeptides … or ….&quot; Should be &quot;nonapeptides … and ….&quot;</p></disp-quote><p>Line 64 has been corrected accordingly.</p><disp-quote content-type="editor-comment"><p>2. A lot of acronyms were used without being clearly defined. Such as Line 66 &quot;4-aa&quot; ; Line 96 &quot;MD simulation&quot; &quot;KC&quot; &quot;HC&quot; &quot;KCDR&quot; etc.</p></disp-quote><p>All of the listed acronyms are now clearly defined:</p><p>Line 66: 4-amino acid (aa)</p><p>Line 96: Molecular Dynamics (MD)</p><p>Line 157: The recognition of PvCSPvk210 peptides by 2F2 is mediated mostly by residues localized in Heavy Chain Complementarity-Determining Regions (HCDRs) 1, 2 and 3, and Kappa Chain Complementarity-Determining Regions (KCDRs) 1 and 3.</p><disp-quote content-type="editor-comment"><p>3. Line 161. Figure 3E referenced in this paragraph did not seem to correlate with Figure 3E. None of the residues mentioned were mentioned in the figure.</p></disp-quote><p>As mentioned above in response to Reviewer 2, more labels have now been added to Figure 3E (A9, G10, K.Gly91, K.Phe96,…) in order to highlight the interactions discussed in the text.</p><disp-quote content-type="editor-comment"><p>4. Line 171. No Figure 2E is found.</p></disp-quote><p>This correction has been made.</p><disp-quote content-type="editor-comment"><p>5. Lack of consistency. Line 66 &quot;motifs of Pf and P.berghei CSP …&quot;</p></disp-quote><p>Line 66 was corrected to: …Pf and P. berghei (Pb) CSP…</p><disp-quote content-type="editor-comment"><p>6. Please use a consistent number format for all Kd values. Such as 1-decimal place is used in Figure 3A and 2- and 3- decimal places were used in Figure 4A.</p></disp-quote><p>K<sub>D</sub> values have been updated throughout the manuscript to three significant figures.</p><disp-quote content-type="editor-comment"><p>7. Line 201. Figure 3E should be Figure 4E.</p></disp-quote><p>Line 201 has been revised accordingly.</p><disp-quote content-type="editor-comment"><p>8. Line 618. &quot;HC residues are shown in green and KC residues are shown in grey&quot; better written as &quot;HC is shown in green and KC is shown in grey&quot;.</p></disp-quote><p>Line 618 has been revised accordingly.</p><disp-quote content-type="editor-comment"><p>9. Line 63. &quot;HC residues are shown in blue and KC residues are shown in grey&quot; better written as &quot;HC is shown in green and KC is shown in grey&quot;.</p></disp-quote><p>Line 63 was revised accordingly.</p><disp-quote content-type="editor-comment"><p>10. Figure 5C figure legend. The definition of &quot;Green highlight&quot; and &quot;Yellow highlight&quot; seems swapped. Please check accuracy.</p></disp-quote><p>The Figure 5C caption has revised accordingly.</p><disp-quote content-type="editor-comment"><p>11. Line 303. Please use &quot;proline&quot; and &quot;glycine&quot; instead of P and G.</p></disp-quote><p>The nomenclature on line 303 has been revised accordingly.</p></body></sub-article></article>